0000844985 2026-01-01 2026-06-30 0000844985 2026-08-14 0000844985 2026-06-30 0000844985 2025-12-31 0000844985 2026-04-01 2026-06-30 0000844985 2025-04-01 2025-06-30 0000844985 2025-01-01 2025-06-30 0000844985 posc:SeriesAPreferredStocksMember 2025-12-31 0000844985 posc:SeriesBPreferredStocksMember 2025-12-31 0000844985 us-gaap:PreferredStockMember 2025-12-31 0000844985 us-gaap:CommonStockMember 2025-12-31 0000844985 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000844985 us-gaap:RetainedEarningsMember 2025-12-31 0000844985 us-gaap:TreasuryStockCommonMember 2025-12-31 0000844985 posc:SeriesAPreferredStocksMember 2026-03-31 0000844985 posc:SeriesBPreferredStocksMember 2026-03-31 0000844985 us-gaap:PreferredStockMember 2026-03-31 0000844985 us-gaap:CommonStockMember 2026-03-31 0000844985 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0000844985 us-gaap:RetainedEarningsMember 2026-03-31 0000844985 us-gaap:TreasuryStockCommonMember 2026-03-31 0000844985 2026-03-31 0000844985 posc:SeriesAPreferredStocksMember 2024-12-31 0000844985 posc:SeriesBPreferredStocksMember 2024-12-31 0000844985 us-gaap:CommonStockMember 2024-12-31 0000844985 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000844985 us-gaap:RetainedEarningsMember 2024-12-31 0000844985 us-gaap:TreasuryStockCommonMember 2024-12-31 0000844985 2024-12-31 0000844985 posc:SeriesAPreferredStocksMember 2025-03-31 0000844985 posc:SeriesBPreferredStocksMember 2025-03-31 0000844985 us-gaap:CommonStockMember 2025-03-31 0000844985 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000844985 us-gaap:RetainedEarningsMember 2025-03-31 0000844985 us-gaap:TreasuryStockCommonMember 2025-03-31 0000844985 2025-03-31 0000844985 posc:SeriesAPreferredStocksMember 2026-01-01 2026-03-31 0000844985 posc:SeriesBPreferredStocksMember 2026-01-01 2026-03-31 0000844985 us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0000844985 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0000844985 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0000844985 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0000844985 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-31 0000844985 2026-01-01 2026-03-31 0000844985 posc:SeriesAPreferredStocksMember 2026-04-01 2026-06-30 0000844985 posc:SeriesBPreferredStocksMember 2026-04-01 2026-06-30 0000844985 us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0000844985 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0000844985 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0000844985 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0000844985 us-gaap:TreasuryStockCommonMember 2026-04-01 2026-06-30 0000844985 posc:SeriesAPreferredStocksMember 2025-01-01 2025-03-31 0000844985 posc:SeriesBPreferredStocksMember 2025-01-01 2025-03-31 0000844985 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000844985 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000844985 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000844985 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0000844985 2025-01-01 2025-03-31 0000844985 posc:SeriesAPreferredStocksMember 2025-04-01 2025-06-30 0000844985 posc:SeriesBPreferredStocksMember 2025-04-01 2025-06-30 0000844985 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000844985 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000844985 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0000844985 us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0000844985 posc:SeriesAPreferredStocksMember 2026-06-30 0000844985 posc:SeriesBPreferredStocksMember 2026-06-30 0000844985 us-gaap:PreferredStockMember 2026-06-30 0000844985 us-gaap:CommonStockMember 2026-06-30 0000844985 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0000844985 us-gaap:RetainedEarningsMember 2026-06-30 0000844985 us-gaap:TreasuryStockCommonMember 2026-06-30 0000844985 posc:SeriesAPreferredStocksMember 2025-06-30 0000844985 posc:SeriesBPreferredStocksMember 2025-06-30 0000844985 us-gaap:CommonStockMember 2025-06-30 0000844985 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000844985 us-gaap:RetainedEarningsMember 2025-06-30 0000844985 us-gaap:TreasuryStockCommonMember 2025-06-30 0000844985 2025-06-30 0000844985 2025-01-01 2025-12-31 0000844985 2022-01-01 2022-12-31 0000844985 us-gaap:EquipmentMember 2025-01-01 2025-12-31 0000844985 us-gaap:MaintenanceMember 2026-04-01 2026-06-30 0000844985 us-gaap:MaintenanceMember 2025-04-01 2025-06-30 0000844985 us-gaap:MaintenanceMember 2026-01-01 2026-06-30 0000844985 us-gaap:MaintenanceMember 2025-01-01 2025-06-30 0000844985 us-gaap:EquipmentMember 2026-06-30 0000844985 us-gaap:EquipmentMember 2025-12-31 0000844985 posc:OtherMember 2026-06-30 0000844985 posc:OtherMember 2025-12-31 0000844985 posc:StockOptionsMember 2026-01-01 2026-06-30 0000844985 posc:StockOptionsMember 2025-01-01 2025-06-30 0000844985 us-gaap:WarrantMember 2026-01-01 2026-06-30 0000844985 us-gaap:WarrantMember 2025-01-01 2025-06-30 0000844985 us-gaap:SeriesAPreferredStockMember 2026-01-01 2026-06-30 0000844985 us-gaap:SeriesAPreferredStockMember 2025-01-01 2025-06-30 0000844985 us-gaap:SeriesBPreferredStockMember 2026-01-01 2026-06-30 0000844985 us-gaap:SeriesBPreferredStockMember 2025-01-01 2025-06-30 0000844985 posc:CommonStocksMember 2026-01-01 2026-06-30 0000844985 posc:NotePayable1RelatedPartyMember posc:ShareholderAndDirectorMember 2026-01-01 2026-06-30 0000844985 posc:NotePayable2RelatedPartyMember posc:ShareholderAndDirectorMember 2026-01-01 2026-06-30 0000844985 posc:NotePayable3RelatedPartyMember posc:ShareholderAndDirectorMember 2026-01-01 2026-06-30 0000844985 posc:NotePayable4RelatedPartyMember posc:ShareholderAndDirectorMember 2026-01-01 2026-06-30 0000844985 posc:NotePayable1RelatedPartyMember posc:ShareholderAndDirectorMember 2026-06-30 0000844985 posc:NotePayable2RelatedPartyMember posc:ShareholderAndDirectorMember 2026-06-30 0000844985 posc:NotePayable3RelatedPartyMember posc:ShareholderAndDirectorMember 2026-06-30 0000844985 posc:NotePayable4RelatedPartyMember posc:ShareholderAndDirectorMember 2026-06-30 0000844985 posc:NotePayable1RelatedPartyMember posc:ShareholderAndDirectorMember 2024-12-31 0000844985 posc:NotePayable2RelatedPartyMember posc:ShareholderAndDirectorMember 2024-12-31 0000844985 posc:NotePayable3RelatedPartyMember posc:ShareholderAndDirectorMember 2024-12-31 0000844985 posc:NotePayable4RelatedPartyMember posc:ShareholderAndDirectorMember 2024-12-31 0000844985 us-gaap:NotesPayableCurrent posc:ShareholderAndDirectorMember 2024-12-31 0000844985 posc:NotePayable1RelatedPartyMember posc:ShareholderAndDirectorMember 2025-01-01 2025-12-31 0000844985 posc:NotePayable2RelatedPartyMember posc:ShareholderAndDirectorMember 2025-01-01 2025-12-31 0000844985 posc:NotePayable3RelatedPartyMember posc:ShareholderAndDirectorMember 2025-01-01 2025-12-31 0000844985 posc:NotePayable4RelatedPartyMember posc:ShareholderAndDirectorMember 2025-01-01 2025-12-31 0000844985 us-gaap:NotesPayableCurrent posc:ShareholderAndDirectorMember 2025-01-01 2025-12-31 0000844985 posc:NotePayable1RelatedPartyMember posc:ShareholderAndDirectorMember 2025-12-31 0000844985 posc:NotePayable2RelatedPartyMember posc:ShareholderAndDirectorMember 2025-12-31 0000844985 posc:NotePayable3RelatedPartyMember posc:ShareholderAndDirectorMember 2025-12-31 0000844985 posc:NotePayable4RelatedPartyMember posc:ShareholderAndDirectorMember 2025-12-31 0000844985 us-gaap:NotesPayableCurrent posc:ShareholderAndDirectorMember 2025-12-31 0000844985 us-gaap:NotesPayableCurrent posc:ShareholderAndDirectorMember 2026-01-01 2026-06-30 0000844985 us-gaap:NotesPayableCurrent posc:ShareholderAndDirectorMember 2026-06-30 0000844985 posc:ShareholderAndDirectorMember 2023-04-30 0000844985 posc:NotePayable2RelatedPartyMember posc:ShareholderAndDirectorMember 2023-04-30 0000844985 2023-12-31 0000844985 2024-03-31 0000844985 posc:ShareholderAndDirectorMember 2024-03-31 0000844985 2024-01-01 2024-12-31 0000844985 posc:ShareholderAndDirectorMember 2024-09-30 0000844985 posc:WarrantsMember 2025-01-01 2025-12-31 0000844985 posc:ShareholderAndDirectorMember 2024-08-31 0000844985 posc:NotePayable3RelatedPartyMember posc:ShareholderAndDirectorMember 2024-08-31 0000844985 posc:ShareholderAndDirectorMember 2024-12-31 0000844985 posc:ShareholderAndDirectorMember 2025-02-28 0000844985 posc:NotePayable4RelatedPartyMember posc:ShareholderAndDirectorMember 2025-02-28 0000844985 2025-07-01 2025-07-08 0000844985 2025-06-26 2025-08-31 0000844985 2022-03-01 2022-03-17 0000844985 posc:FirstThreeYearsMember 2022-03-17 0000844985 posc:LastTwoYearsMember 2022-03-17 0000844985 2025-10-27 0000844985 us-gaap:SeriesAPreferredStockMember 2026-03-18 0000844985 us-gaap:SeriesBPreferredStockMember 2026-03-18 0000844985 us-gaap:SeriesCPreferredStockMember 2026-03-18 0000844985 us-gaap:SeriesDPreferredStockMember 2026-03-18 0000844985 us-gaap:SeriesEPreferredStockMember 2026-03-18 0000844985 us-gaap:SeriesFPreferredStockMember 2026-03-18 0000844985 us-gaap:SeriesGPreferredStockMember 2026-03-18 0000844985 us-gaap:SeriesHPreferredStockMember 2026-03-18 0000844985 posc:SeriesSPreferredStockMember 2026-03-18 0000844985 us-gaap:SeriesAPreferredStockMember 2025-12-31 0000844985 us-gaap:SeriesAPreferredStockMember 2026-06-30 0000844985 us-gaap:SeriesBPreferredStockMember 2026-06-30 0000844985 us-gaap:SeriesAPreferredStockMember 2025-10-30 0000844985 us-gaap:SeriesBPreferredStockMember 2025-10-30 0000844985 us-gaap:SeriesAPreferredStockMember 2025-10-29 2025-10-30 0000844985 us-gaap:SeriesBPreferredStockMember 2025-10-29 2025-10-30 0000844985 posc:ServicesMember 2026-01-01 2026-06-30 0000844985 us-gaap:CommonStockMember posc:ServicesMember 2026-01-01 2026-06-30 0000844985 posc:ServicesMember 2026-06-30 0000844985 us-gaap:CommonStockMember 2026-01-01 2026-06-30 0000844985 posc:CashPaymentsMember 2025-12-31 0000844985 srt:MinimumMember posc:CashPaymentsMember 2025-12-31 0000844985 srt:MaximumMember posc:CashPaymentsMember 2025-12-31 0000844985 us-gaap:RelatedPartyMember posc:CashPaymentsMember 2025-12-31 0000844985 posc:PrincipalStockholderMember posc:CashPaymentsMember 2025-12-31 0000844985 us-gaap:RelatedPartyMember 2026-01-01 2026-06-30 0000844985 srt:MinimumMember us-gaap:RelatedPartyMember 2026-01-01 2026-06-30 0000844985 srt:MaximumMember us-gaap:RelatedPartyMember 2026-01-01 2026-06-30 0000844985 us-gaap:RelatedPartyMember 2026-06-30 0000844985 2021-05-31 0000844985 2025-11-05 0000844985 2025-11-04 2025-11-05 0000844985 posc:BoardOfDirectorsChairmanAndPresidentMember 2025-11-05 0000844985 posc:BoardsOfDirectorsMember 2025-11-05 0000844985 us-gaap:WarrantMember 2024-12-31 0000844985 us-gaap:WarrantMember 2024-01-01 2024-12-31 0000844985 us-gaap:WarrantMember 2025-01-01 2025-12-31 0000844985 us-gaap:WarrantMember 2025-12-31 0000844985 us-gaap:WarrantMember 2026-06-30 0000844985 us-gaap:SubsequentEventMember 2026-08-13 0000844985 us-gaap:SubsequentEventMember 2026-08-01 2026-08-13 iso4217:USD shares iso4217:USD shares pure false 2026 Q2 --12-31 0000844985

-2199169

-1838293

-147136248

-660847

2025-07-08 2030-07-08

160107

2022-06-01 2027-05-31

10-Q true 2026-06-30 false 000-24092 POSITRON CORPORATION TX 76-0083622 3784 Commerce Ct Suite 100 North Tonawanda NY 14120 (317) 576-0183 Common Stock, par value $0.0001 POSC Yes Yes Non-accelerated Filer true false false 32846326

357173

2520466

17561

8333

680000

52014

130387

1106748

3339186

86550

105752

160107

179711

375000

1728405

3999649

119399

81512

452181

407017

210000

120000

875000

1200000

32778

30612

563000

2252358

2402141

136894

153686

136894

153686

2389252

2555827

0.0001

10000000

0.0001

100000000

32846326

32799451

3285

3280

146472491

146377996

-147136248

-144937079

750

375

-660847

1443822

1728405

3999649

111822

120118

222822

239452

376732

402433

1014550

779465

-264910

-282315

-791728

-540013

539004

887675

1377142

2107474

-803914

-1169990

-2168870

-2647487

21815

29918

45164

64844

4329 9166 14865 9208

17486

20752

30299

55636

-821400

-1190742

-2199169

-2703123

-0.03

-0.04

-0.07

-0.09

32849451

31305008

32840145

30259336

32799451

3280

146377996

-144937079

750

-375

1443822

50000

94495

94500

-1377769

32849451

3285

146472491

-146314848

750

-375

160553

-3125

-821400

32846326

3285

146472491

-147136248

750

-375

-660847

435085

192000

27305008

2731

133047521

-134333687

750

-375

-656725

8000000

800

7999200

8000000

-4000000

-400

-2499600

-2500000

2936 2936

41414

-1512381

435085

192000

31305008

3131

138591471

-135846068

750

-375

3375244

100000

176990

177000

-1190742

435085

192000

31405008

3141

138768461

-137036810

750

-375

2361502

-2199169

-2703123

19604 8066

19202

9300

-94500

-177000

2936

9228

-8334

-78373

8108

37887

28915

45164

106907

90000

53670

-14626

-8063

-1838293

-2324166

8000000

2500000

100000

325000

350000

-325000

5250000

-2163293

2925834

2520466

69791

357173

2995625

41414

<p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zm1fbkP5kQS4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note 1 - Organization and Nature of Operations Organization and Nature of Operations Positron Corporation (collectively, “we,” “us,” “our” or the “Company”), a Texas Corporation (originally incorporated on December 20, 1983). Positron Corporation is a medical technology company that co-develops, manufactures, and sells PET and PET-CT imaging systems and related services to healthcare providers. The Company focuses on cardiac PET imaging and is expanding into broader clinical applications, including oncology. Positron collaborates with its strategic partner, Neusoft Medical Systems, to support product development, manufacturing, and innovation. Basis of Presentation The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited financial statements contain all of the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of June 30, 2026 and the results of operations and cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2026 are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 31, 2026. Management acknowledges its responsibility for the preparation of the accompanying unaudited financial statements which reflect all adjustments, consisting of normal recurring adjustments, considered necessary in its opinion for a fair statement of its financial position and the results of its operations for the periods presented. Liquidity, Going Concern and Management’s Plans These unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying unaudited financial statements, for the six months ended June 30, 2026, the Company had: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Net loss of $2,199,169; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Net cash used in operations was $1,838,293</td> </tr></table> Additionally, at June 30, 2026, the Company had: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Accumulated deficit of $147,136,248</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Stockholders’ deficit of $660,847; and</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Working capital deficiency of $1,145,610</td> </tr></table> The Company has cash on hand of $357,173 at June 30, 2026. The Company does not expect to generate sufficient revenues and positive cash flows from operations sufficiently to meet its current obligations. However, the Company may seek to raise debt or equity-based capital at favorable terms, though such terms are not certain. These factors create substantial doubt about the Company’s ability to continue as a going concern within the twelve-month period subsequent to the date that these financial statements are issued. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management’s strategic plans include the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Execute business operations more fully during the current year;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Expand its reach within nuclear cardiology with the launch of our PET-CT system which provides greater features and functions now available to nuclear cardiologists and their diagnostic capabilities;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Enter the vast oncology market with its new PET-CT system with a faster, smaller, more economical solution for practices, hospitals, and patients;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Explore and execute of prospective strategic and partnership opportunities; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Pursue to “Up-List” to a more prominent publicly reporting exchange.</td></tr></table>

1983-12-20 1145610

357173

Note 2 - Summary of Significant Accounting Policies Business Segments and Expense Disclosure The Company follows Financial Accounting Standards Board (FASB) ASC 280, Segment Reporting, which requires public entities to report financial and descriptive information about their reportable operating segments. FASB ASC 280-10-50-1 states that an operating segment is a component of a public entity that: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Engages in business activities from which it may earn revenues and incur expenses;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Has operating results that are regularly reviewed by the Chief Operating Decision Maker (CODM), who is the Company’s Chief Executive Officer, to make decisions about resource allocation and performance assessment; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Has discrete financial information available.</td></tr></table> Under ASC 280-10-50-10, a public entity is required to report separately only those operating segments that meet certain quantitative thresholds. However, as specified in FASB ASC 280-10-50-11, if a company’s business activities are managed as a single operating segment and reviewed on a basis, the company may report as a single segment. The Company has determined that it operates as one reportable segment, as its CODM reviews the business as a whole rather than by distinct business components. Significant expenses within loss from operations, as well as within net loss, include cost of sales and general and administrative expenses, which are each presented separately on the accompanying Statements of Operations. Other segment items within net loss include interest expense, net, and amortization of debt discount. In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which requires all public entities, including public entities with a single reportable segment, to provide in interim and annual periods one or more measures of segment profit or loss used by the chief operating decision maker to allocate resources and assess performance. Additionally, the standard requires disclosures of significant segment expenses and other segment items as well as incremental qualitative disclosures. The Company adopted ASU 2023-07 for its annual reporting period ended December 31, 2024 and for interim periods beginning January 1, 2025, on a retrospective basis. The adoption did not change the way the Company identifies its reportable segments and, accordingly, did not have a material impact on the Company’s segment-related disclosures. The adoption of 2023-07 did not change the way that the Company identifies its reportable segments and, as a result, did not have a material impact on the Company’s segment-related disclosures. Use of Estimates and Assumptions The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the recognition of revenues and expenses during the reporting period. Actual results may differ from these estimates, and such differences could be material. Changes in estimates are recorded in the period in which they become known and are accounted for prospectively. The Company bases its estimates on historical experience, industry trends, and other relevant factors, incorporating both quantitative and qualitative assessments that it believes are reasonable under the circumstances. Significant estimates during the six months ended June 30, 2026 and 2025 include: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Allowance for doubtful accounts and other receivables </td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Inventory reserves and classifications </td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Valuation of equity based instruments </td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Estimated useful lives of property and equipment </td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Implicit interest rate in right-of-use operating leases </td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Uncertain tax positions </td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Valuation allowance on deferred tax assets </td></tr></table> Risks and Uncertainties The Company operates in a highly competitive industry that is subject to intense market dynamics, shifting consumer demand, and economic fluctuations. The Company’s operations are exposed to significant financial, operational, and strategic risks, including potential business disruptions, supply chain constraints, and liquidity challenges. In accordance with FASB ASC 275, “Risks and Uncertainties,” the Company evaluates and discloses risks that could materially affect its financial condition, results of operations, and business outlook. Key factors contributing to variability in sales and earnings include: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">1.</td><td style="text-align: justify">Industry Cyclicality – The Company’s financial performance is affected by industry trends, seasonality, and shifts in market demand.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">2.</td><td style="text-align: justify">Macroeconomic Conditions– Economic downturns, inflationary pressures, interest rate changes, global tariff policy, and geopolitical risks may impact consumer purchasing behavior and the Company’s revenue streams.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">3.</td><td style="text-align: justify">Pricing Volatility– The cost and availability of raw materials, supply chain disruptions, and competitive pricing pressures can lead to fluctuations in gross margins and profitability.</td></tr></table> Given these uncertainties, the Company faces challenges in accurately forecasting financial performance and may experience material risks affecting liquidity, business continuity, and long-term strategic growth. The Company continuously assesses these risks and implements measures to mitigate their potential impact. Fair Value of Financial Instruments The Company accounts for financial instruments in accordance with Financial Accounting Standards Board (FASB) ASC 820, “Fair Value Measurements”, which establishes a framework for measuring fair value and requires related disclosures. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the Company’s principal market or, if none exists, the most advantageous market for the asset or liability. Fair Value Hierarchy FASB ASC 820 requires the use of observable inputs whenever available and establishes a three-tier hierarchy for measuring fair value: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Level 1 – Quoted market prices (unadjusted) for identical assets or liabilities in active markets.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Level 2 – Observable inputs other than quoted prices in active markets, such as quoted prices for similar assets and liabilities or inputs that are directly or indirectly observable.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Level 3 – Unobservable inputs that require significant judgment, including management assumptions and estimates based on available market data.</td></tr></table> The classification of an asset or liability within the hierarchy is based on the lowest level of input that is significant to the fair value measurement. Level 3 valuations generally require more judgment and complexity, often involving a combination of cost, market, or income approaches, as well as assumptions about market conditions, pricing, and other factors. Fair Value Determination The Company assesses the fair value of its financial instruments and, where appropriate, may engage external valuation specialists to assist in determining fair value. While management believes that recorded fair values are reasonable, they may not necessarily reflect net realizable values or future fair values. Financial Instruments Carried at Historical Cost The Company’s financial instruments—including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses (including related party balances)—are recorded at historical cost. As of June 30, 2026 and December 31, 2025, respectively, the carrying amounts of these instruments approximated their fair values due to their short-term maturities. Cash and Cash Equivalents and Concentration of Credit Risk For purposes of the statements of cash flows, the Company considers all highly liquid investments with original maturities of three months or less from the date of purchase, including money market accounts and short-term certificates of deposit, to be cash equivalents. At June 30, 2026, the Company did not hold any cash equivalents At December 31, 2025, the Company’s cash equivalents consisted of a money market account. The Company is exposed to credit risk on its cash and cash equivalents in the event of default by the financial institutions to the extent account balances exceed the amount insured by the FDIC, which is $250,000. At June 30, 2026 and December 31, 2025, the Company had cash in excess of the insured FDIC limit of $112,178 and $2,272,502, respectively. From time to time the Company has amounts that exceed the FDIC insured amount but does not expect any non-performance. Accounts Receivable The Company accounts for accounts receivable in accordance with FASB ASC 326, “Financial Instruments – Credit Losses. Receivables are recorded at their net realizable value, which represents the amount management expects to collect from outstanding customer balances. The Company extends credit to customers based on an evaluation of their financial condition and other factors. The Company does not require collateral, and interest is not accrued on overdue accounts receivable. Allowance for Expected Credit Losses The Company has elected the practical expedient in Accounting Standards Update (ASU) 2025-05 for its current (short-term) accounts receivable. Under this practical expedient, the Company assumes that current economic conditions as of the balance sheet date will not change over the remaining life of these receivables when estimating expected credit losses. Management periodically assesses the collectability of accounts receivable and establishes an allowance for expected credit losses as needed. The allowance is determined based on: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">A review of outstanding accounts,</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Historical collection experience, and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Current economic conditions.</td></tr></table> Accounts deemed uncollectible are written off against the allowance when determined to be uncollectible. Allowance for expected credit losses was $0 at June 30, 2026 and December 31, 2025, respectively. Inventory Inventory consists of scanning equipment and is stated at the lower of cost or net realizable value (“LCNRV”) using the first-in, first-out (“FIFO”) method. Management assesses the recoverability of inventory each reporting period and records write-downs to net realizable value when the carrying value exceeds estimated proceeds from sale, less costs to complete and sell. Factors considered in this assessment include: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Market conditions;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Net realizable value based on estimated selling price and selling costs; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Inventory turnover trends.</td></tr></table> During the year ended December 31, 2025, the Company recorded an inventory write-down of $576,862 (included in cost of sales) to reduce the carrying value of its scanning equipment to net realizable value. Net realizable value was determined based on the estimated selling price under an existing sales contract, less estimated costs to complete and sell the equipment. A customer deposit related to this contract is recorded in deferred revenue (see the revenue recognition discussion below). During the six months ended June 30, 2026, the Company incurred $238,352 of additional equipment costs to ready the unit for sale and recorded a corresponding inventory write-down of $238,352, which is included in cost of goods sold. The machine will be delivered to the customer upon completion of installment payments under an executed sale agreement and upon FDA approval; the corresponding consideration received to date has been recorded as deferred revenue (see below). At June 30, 2026 and December 31, 2025, inventory was as follows: Schedule of Inventory <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Classification</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 62%; text-align: left">Finished systems</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_c20260630_zuOkXFt016gf" style="width: 16%; text-align: right" title="Finished systems">918,352</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_c20251231_zTKbYYH9fK98" style="width: 16%; text-align: right" title="Finished systems">1,256,862</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Less: writedown of inventory to net realizable value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--InventoryWriteDown_iN_di_c20260101__20260630_zmGGjOBcPre4" style="border-bottom: Black 1pt solid; text-align: right" title="Less: writedown of inventory to net realizable value">(238,352</td><td style="padding-bottom: 0.5pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--InventoryWriteDown_iN_di_c20250101__20251231_zWUTno3Jtz6" style="border-bottom: Black 1pt solid; text-align: right" title="Less: writedown of inventory to net realizable value">(576,862</td><td style="padding-bottom: 0.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Total Inventory</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--InventoryNet_iI_c20260630_zcGyjiBt9jO5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Inventory">680,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--InventoryNet_iI_c20251231_zmZtdPe06lV8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Inventory">680,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Deposits Deposits represent amounts paid to a third-party manufacturer toward the purchase of a PET-CT system, the recoverability of which is contingent upon successful equipment validation and U.S. Food and Drug Administration (FDA) clearance. Activity in deposits for the six months ended June 30, 2026 and the year ended December 31, 2025 was as follows: Schedule of Deposits <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td style="width: 42%; text-align: left">December 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Deposits_iS_c20250101__20251231_zusvzQ62rbL2" style="width: 5%; text-align: right" title="Deposits Beginning">375,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">No activity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--DepositsActivity_c20250101__20251231_zRxn8lY6ZVul" style="text-align: right" title="No activity">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">December 31, 2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--Deposits_iS_c20260101__20260630_zuaIBn12wECi" style="text-align: right" title="Deposits Beginning">375,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">No activity</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--DepositsActivity_c20260101__20260630_zliFbwMgPSDd" style="border-bottom: Black 1pt solid; text-align: right" title="No activity">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--Deposits_iE_c20260101__20260630_zMNvkGVazZ9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Deposits Ending">375,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> In 2022, the Company paid $1,000,000 for equipment from its manufacturing partner, Neusoft Medical Systems, In connection with the same transaction, the Company agreed to pay a Non-Recurring Engineering (NRE) Fee of $700,000 to the manufacturer for research, development, and technology transfer services, payable as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">$210,000 paid in 2022; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">$490,000 paid in 2025.</td></tr></table> Because the equipment has not received FDA clearance, the $<span id="xdx_906_eus-gaap--GeneralAndAdministrativeExpense_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zUsa8LxaomU1" title="General and Administrative Expense">490,000 paid in 2025 was charged to general and administrative expense in the accompanying statements of operations for the year ended December 31, 2025. If the equipment fails validation or does not receive FDA clearance, the Company has the contractual right to return the inventory and obtain a refund of the $1,000,000 purchase price, less applicable shipping and handling costs. The manufacturer has also agreed to provide a one-year warranty on the equipment and related software, commencing upon closing of the equipment purchase. Concentrations The Company evaluates and discloses significant concentrations of risk in accordance with FASB ASC 275-10, “Risks and Uncertainties”. These risks may arise from customer concentrations, vendor reliance, geographic dependence, or other economic factors that could materially impact the Company’s financial position, results of operations, and cash flows. A concentration exists when a single customer, supplier, or market accounts for a significant portion (typically greater than 10%) of the Company’s total revenues, accounts receivable, or vendor purchases For the six months ended June 30, 2026 and 2025, respectively, the Company has no such concentrations. Property and Equipment Property and equipment are recorded at cost, net of accumulated depreciation, in accordance with FASB ASC 360, “Property, Plant, and Equipment.” Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance expenditures that do not materially extend the useful life of an asset are expensed as incurred. Significant improvements or upgrades that increase the asset’s productivity, efficiency, or useful life are capitalized. Upon disposal or sale of property and equipment, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in the statement of operations. The Company evaluates the carrying value of property and equipment whenever events or changes in circumstances indicate that the asset may be impaired. If impairment indicators exist, the Company assesses recoverability based on the undiscounted future cash flows expected from the use and disposition of the asset. If the carrying amount exceeds the estimated recoverable amount, an impairment loss is recognized. <p id="xdx_84A_ecustom--FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyTextBlock_zbJgbvvgtBnj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Financial Instruments with Characteristics of Both Liabilities and Equity The Company evaluates equity or liability classification for freestanding financial instruments, including convertible preferred stock, warrants, and options, pursuant to the guidance under FASB ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”). The Company classifies as liabilities all freestanding financial instruments that are (i) mandatorily redeemable, (ii) represent an obligation to repurchase the Company’s equity shares by transferring assets, or (iii) represent an unconditional obligation (or conditional obligation if the financial instrument is not an outstanding share) to issue a variable number of shares predominantly based on a fixed monetary amount, variations in something other than the fair value of the Company’s equity shares, or variations inversely related to changes in fair value of the Company’s equity shares. If a freestanding financial instrument does not represent an outstanding equity share and does not meet liability classification under ASC 480, the Company then assesses whether the freestanding financial instrument is indexed to its own stock and meets equity classification pursuant to FASB ASC 815-40, “Contracts in Entity’s Own Equity” (“ASC 815”). The Company further assesses whether the freestanding financial instruments should be classified as temporary equity. Freestanding financial instruments that are redeemable for cash or other assets at a fixed or determinable date, at the option of the holder, or upon the occurrence of an event are classified in temporary equity in accordance with FASB ASC 480. Otherwise, the freestanding financial instruments are classified in permanent equity. Conversion and Extinguishment of Derivative Liabilities When a debt instrument with an embedded conversion option (e.g., convertible debt or warrants) is converted into shares of common stock or repaid, the Company: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Records the newly issued shares at fair value;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Derecognizes all related debt, derivative liabilities, and unamortized debt discounts; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Recognizes a gain or loss on debt extinguishment, if applicable.</td></tr></table> For equity-based derivative liabilities (e.g., warrants) that are extinguished, any remaining liability balance is reclassified to additional paid-in capital. <p id="xdx_840_ecustom--OriginalIssueDiscountsAndOtherDebtDiscountsPolicyTextBlock_zcWdWNQR9Fia" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Original Issue Discounts and Other Debt Discounts The Company accounts for original issue discounts (OID) and other debt discounts in accordance with FASB ASC 835-30, “Interest—Imputation of Interest”. These discounts are recorded as a reduction of the carrying amount of the related debt and are amortized to interest expense over the term of the debt using the effective interest method, unless the straight-line method is materially similar. Original Issue Discounts (OID) For certain notes issued, the Company may provide the debt holder with an original issue discount (OID), which is recorded as a debt discount, reducing the face value of the note. The discount is amortized to interest expense over the term of the debt in the Statements of Operations. Stock and Other Equity Issued with Debt The Company may issue common stock or other equity instruments in connection with debt issuance. When stock is issued, it is recorded at relative fair value and treated as a debt discount, reducing the carrying amount of the note. These discounts are amortized to interest expense over the life of the debt. The combined debt discounts, including OID and stock-related discounts, cannot exceed the face amount of the debt. Debt Issuance Costs Debt issuance costs, including fees paid to lenders or third parties, are capitalized as a debt discount and amortized to interest expense over the life of the debt. These costs are presented as a direct deduction from the carrying amount of the debt liability rather than as a separate asset. Warranties and Maintenance Contracts Product Warranties The Company provides an assurance-type warranty on its products covering defects in design, materials, and workmanship for a period of one year from customer acceptance. Assurance-type warranties do not represent a separate performance obligation under ASC 606; rather, the estimated cost of fulfilling the warranty obligation is accrued at the time of product delivery in accordance with ASC 460-10-25-5 and ASC 450-20-25, when the obligation is probable and reasonably estimable. The warranty provision is based on historical trends in defect nature, frequency, and average cost of claims for each product line. These estimates are reassessed each reporting period using the best available information, and adjustments are made as necessary. Historically, the Company has incurred insignificant warranty-related costs. At June 30, 2026 and December 31, 2025, no warranty liability was recorded, as the estimated obligation was deemed immaterial. Certain components used in the Company’s products are covered under supplier-provided limited warranties, which include replacement and service coverage for parts. The Company does not have direct responsibility for these supplier warranties. As of June 30, 2026 and December 31, 2025, the Company is not aware of any pending or asserted claims related to product warranty obligations. Maintenance Contracts The Company separately offers post-delivery maintenance contracts to customers. Maintenance contracts are distinct from the Company’s assurance-type product warranty and represent separate performance obligations under ASC 606. Revenue attributable to maintenance contracts is deferred at contract inception and recognized ratably over the maintenance period as the related services are performed. At June 30, 2026 and December 31, 2025, no maintenance contract revenue was deferred. Treasury Stock The Company accounts for treasury stock transactions under the cost method in accordance with FASB ASC 505-30, “Treasury Stock”. Under this method, when the Company repurchases its own shares, the full acquisition cost is recorded as a reduction to stockholders’ equity under the treasury stock account. These shares remain issued but are not considered outstanding and do not participate in dividends or earnings per share calculations. As of June 30, 2026 and December 31, 2025, respectively, the Company had 750 shares of treasury stock recorded at an aggregate cost of $375. Right of Use Assets and Lease Obligations The Company accounts for right-of-use (ROU) assets and lease liabilities in accordance with FASB ASC 842, “Leases”. These amounts reflect the present value of the Company’s estimated future minimum lease payments over the lease term, including any reasonably certain renewal options, discounted using a collateralized incremental borrowing rate. The Company classifies its leases as either operating or finance leases. The Company’s leases primarily consist of operating leases, which are included as Right-of-Use Assets and Operating Lease Liabilities on the balance sheet. Short-Term Leases The Company has elected the short-term lease exemption, whereby leases with a term of 12 months or less are not recorded on the balance sheet. Instead, lease payments are expensed on a straight-line basis over the lease term. Lease Term and Renewal Options In determining the lease term, the Company evaluates whether renewal options are reasonably certain to be exercised. Factors considered include: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">The useful life of leasehold improvements relative to the lease term,</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">The economic performance of the business at the leased location,</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">The comparative cost of renewal rates versus market rates, and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">The presence of any significant economic penalties for non-renewal.</td></tr></table> If a renewal option is deemed reasonably certain to be exercised, the ROU asset and lease liability reflect those additional future lease payments. The Company’s operating leases contain renewal options with no residual value guarantees. Currently, management does not expect to exercise any renewal options, which are therefore excluded in the measurement of lease obligations. Discount Rate and Lease Liability Measurement Since the implicit rate in the leases is not readily determinable, the Company applies an incremental borrowing rate that represents the rate it would incur to borrow on a collateralized basis over a similar term and currency environment. Lease Impairment The Company evaluates ROU assets for impairment indicators whenever events or changes in circumstances suggest the carrying amount may not be recoverable. See Note 6 for further discussion on lease cancellation during the year December 31, 2025. Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized when or as control of promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, performance obligations are satisfied. Nature of Services and Performance Obligations The Company generates revenue primarily from clinical, technical, and maintenance service contracts that provide customers with ongoing product support and from sales of equipment. These contracts are generally one-year agreements that automatically renew for successive one-year periods unless terminated by either party with at least 90 days’ notice. The Company considers only the noncancelable initial term and any renewal periods for which the customer has a material right when determining the contract term and performance obligations. Each maintenance contract represents a single distinct performance obligation. The various service elements - including priority response, 24/7 clinical and technical support, parts and labor, preventative maintenance, software upgrades, uptime guarantees, remote diagnostic capabilities, daily quality assurance inspections, and applications training - are highly integrated and interdependent. They are not separately identifiable from one another and are accounted for as a single stand-ready performance obligation that is satisfied continuously over the contract term. Significant Judgments In applying ASC 606, the Company makes the following significant judgments that affect the timing and amount of revenue recognized: (i) the Company concluded that all services under each maintenance contract constitute a single performance obligation because they are highly interrelated and provide a combined integrated service to the customer; (ii) for maintenance contracts, the Company uses a time-based, straight-line output method to measure progress, which it has determined faithfully depicts the Company’s performance as the customer simultaneously receives and consumes the benefits of the services; and (iii) for equipment sales, the Company applies judgment in assessing when control transfers to the customer. No changes to these judgments have occurred during the periods presented. Transaction Price and Allocation The transaction price is the fixed fee stated in each contract. The Company does not offer refunds, rebates, discounts, or variable pricing incentives. Maintenance contract fees are typically billed monthly in advance with payment due within 30 days. As permitted by the practical expedient in ASC 606-10-32-18, the Company does not adjust the transaction price for the effects of a significant financing component when the period between transfer of control of the good or service and customer payment is one year or less. Because each contract contains a single performance obligation, the entire transaction price is allocated to that obligation. Revenue Recognition – Timing The Company recognizes revenue either over time or at a point in time depending on the nature of the performance obligation. Maintenance contract revenue is recognized over time as the customer simultaneously receives and consumes the benefits of the services as they are provided. Revenue is recognized ratably on a straight-line basis over the contract term. Amounts received in advance of services being provided are recorded as deferred revenue and recognized as revenue as the related performance obligations are satisfied. Equipment sale revenue is recognized at a point in time when control of the equipment transfers to the customer, which occurs upon physical delivery and acceptance of the equipment and where collection is probable. In the three and six months ended June 30, 2026 and 2025, no equipment sale revenue had been recognized, as the conditions for transfer of control had not yet been met. Principal vs. Agent Considerations The Company has determined that it acts as a principal in all revenue transactions. The Company controls the services prior to transfer to the customer, is responsible for fulfilling all contractual obligations including uptime guarantees, bears the risk of performance, and has discretion in establishing contract pricing. Accordingly, revenue is recognized on a gross basis. Contract Balances and Remaining Performance Obligations The Company’s contract liabilities consist of deferred revenue related to maintenance contracts billed in advance and customer deposits on pending equipment sales. These amounts are presented as deferred revenue on the accompanying balance sheets. There were no contract assets as of June 30, 2026 or December 31, 2025. The Company has elected the practical expedient under ASC 606-10-50-14 not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for contracts with an original expected duration of one year or less. Disaggregation of Revenue The following table presents the Company’s revenues disaggregated by type for the six months ended June 30, 2026 and 2025: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>Schedule of Company’s revenues disaggregated</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Sales</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center"> Revenue </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% of Revenues</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center"> Revenue </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% of Revenues</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 40%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Service Income</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_c20260401__20260630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_zW7i7V7qjyd3" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">111,822</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--RevenuesPercentage_pid_dp_uRatio_c20260401__20260630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_zhFAlZfD4xvb" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--Revenues_c20250401__20250630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_zxVMi1S9E5R7" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">120,118</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--RevenuesPercentage_pid_dp_uRatio_c20250401__20250630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_z6aiO33nWGJc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20260401__20260630_zsoxOmh5uRtl" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">111,822</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_ecustom--RevenuesPercentage_pid_dp_uRatio_c20260401__20260630_z7rhIzD7XsEe" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--Revenues_c20250401__20250630_z0Zuum7rYzee" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">120,118</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--RevenuesPercentage_pid_dp_uRatio_c20250401__20250630_zdkGQiAk4AUe" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> Schedule of Company’s revenues disaggregated <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Sales</td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"> Revenue </td><td style="padding-bottom: 1pt; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% of Revenues</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center"> Revenue </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% of Revenues</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 40%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Service Income</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20260101__20260630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_z4hrr0gqSMDh" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">222,822</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--RevenuesPercentage_pid_dp_uRatio_c20260101__20260630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_zy9e4AWIYGp9" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20250101__20250630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_zYT8EiHEM8B5" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">239,452</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--RevenuesPercentage_pid_dp_uRatio_c20250101__20250630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_zZHL2UeLRjwj" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20260101__20260630_zcUDtjvbaY73" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">222,822</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_ecustom--RevenuesPercentage_pid_dp_uRatio_c20260101__20260630_ztjSFOeP1XYd" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_c20250101__20250630_zGjm83vi2Yfh" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">239,452</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--RevenuesPercentage_pid_dp_uRatio_c20250101__20250630_zifcfM8elpx2" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> All revenue recognized in both periods was derived from maintenance service contracts. No equipment sale revenue has been recognized in either period, as transfer of control of the equipment to the customer had not yet occurred as of each respective balance sheet date. Deferred Revenue (Contract Liabilities) Deferred revenue represents consideration received from customers prior to the satisfaction of the related performance obligation. At June 30, 2026 and December 31, 2025, deferred revenue consisted of the following: Schedule of deferred revenue <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Type</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260630_zMMM2i9pBgHc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20251231_zpLwcES9pF79" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%; text-align: left">Customer deposit - equipment sale</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DeferredRevenue_iI_c20260630__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_zdwz5EQmFHlf" style="width: 16%; text-align: right" title="Deferred Revenue">210,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredRevenue_iI_c20251231__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_zeF1stfCdgb" style="width: 16%; text-align: right" title="Deferred Revenue">70,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Customer deposit - other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DeferredRevenue_iI_c20260630__srt--ProductOrServiceAxis__custom--OtherMember_zM6cElrZveL1" style="border-bottom: Black 1pt solid; text-align: right" title="Deferred Revenue">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--DeferredRevenue_iI_c20251231__srt--ProductOrServiceAxis__custom--OtherMember_zhMA6pFfk7jb" style="border-bottom: Black 1pt solid; text-align: right" title="Deferred Revenue">50,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total deferred revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--DeferredRevenue_iI_c20260630_zTA7Mn6eqDD8" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred Revenue">210,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DeferredRevenue_iI_c20251231_zBtWAnRWe6Zd" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred Revenue">120,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Equipment sale deposits represent cumulative installment payments received from customers under executed purchase agreements for medical scanning equipment. Title and physical possession of the equipment transfer to each customer upon receipt of the full contract price, at which point revenue is recognized. During 2026, additional installment payments of $140,000 were received, bringing the aggregate cumulative balance to $210,000 at June 30, 2026. The $50,000 balance at December 31, 2025 represented a payment received from a potential customer. This deposit was refunded in full during 2026. None of the deferred revenue at December 31, 2025 was recognized as revenue during 2026. Maintenance contract amounts represent consideration received from customers prior to the applicable service period and are recognized as revenue ratably as performance obligations are satisfied over the service term. At June 30, 2026, $0 remained deferred, all of which was recognized as revenue during the quarter ended June 30, 2026. Cost of Sales Cost of sales consists of direct expenses incurred in the delivery of services related to the Company’s maintenance contracts. These costs are recognized as incurred and are directly attributable to fulfilling service obligations under customer agreements. The primary components of cost of sales include: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Salaries and Wages – Compensation, payroll taxes, and employee benefits associated with the Company’s service technicians and clinical support staff.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Job-Related Materials and Supplies – Expenses for parts, tools, software upgrades, and consumable materials required to perform maintenance and repairs.</td></tr></table> All costs included in cost of sales are directly related to the provision of contracted maintenance services and align with revenue recognition principles under FASB ASC 606. The Company continually evaluates its cost structure to optimize service delivery while maintaining contractual uptime guarantees and quality assurance standards. Income Taxes The Company accounts for income taxes using the asset and liability method prescribed by FASB ASC 740, “Income Taxes”. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences of differences between the financial reporting and tax bases of assets and liabilities. These amounts are measured using enacted tax rates expected to apply in the periods when temporary differences reverse. The effect of a change in tax rates on deferred tax balances is recognized as income or expense in the period that includes the enactment date. Uncertain Tax Positions The Company evaluates uncertain tax positions which requires that a tax position be recognized in the financial statements only if it is more likely than not (greater than 50% likelihood) to be sustained upon examination by tax authorities. As of June 30, 2026 and 2025, the Company had no uncertain tax positions that qualified for recognition or disclosure in the financial statements. The Company also recognizes interest and penalties related to uncertain tax positions in other expense in the Statement of Operations. No interest and penalties were recorded for the six months ended June 30, 2026 and 2025. Valuation of Deferred Tax Assets The Company’s deferred tax assets include certain future tax benefits, such as net operating losses (NOLs), tax credits, and deductible temporary differences. A valuation allowance is required if it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The Company reviews the realizability of deferred tax assets on a quarterly basis, or more frequently if circumstances warrant, considering both positive and negative evidence. Considered in Valuation Allowance Assessment The Company evaluates multiple factors in determining whether a valuation allowance is necessary, including: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Historical earnings trends (cumulative pre-tax income or losses in the most recent three-year period)</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Future financial projections, including expected taxable income based on long-term estimates of business performance and market conditions</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Statutory carryforward periods for net operating losses and other deferred tax assets</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Prudent and feasible tax planning strategies that could impact the realization of deferred tax assets</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Nature and predictability of temporary differences and the timing of their reversal</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Sensitivity of financial forecasts to external factors such as commodity prices, market demand, and operational risks</td></tr></table> While cumulative three-year losses are a strong indicator that a valuation allowance may be needed, a valuation allowance determination is not solely based on past losses—all available positive and negative evidence must be considered. Valuation Allowance Determination At June 30, 2026 and December 31, 2025, the Company recorded a full valuation allowance against its deferred tax assets, resulting in a net carrying amount of $0. This determination was based on cumulative losses in recent years and the lack of sufficient positive evidence to support the realization of deferred tax assets in the near term. The Company will continue to evaluate its valuation allowance each reporting period and will recognize deferred tax assets in the future if sufficient positive evidence emerges to support their realization. There was no income tax provision recorded for the six months ended June 30, 2026 and 2025, as the Company incurred losses in both periods and maintains a full valuation allowance against its deferred tax assets. Advertising Costs Advertising costs are expensed as incurred. These costs are recognized as operating expenses in the period in which they are incurred and are classified within general and administrative expenses in the statements of operations. The Company does not capitalize direct-response advertising costs, as they do not meet the criteria for deferral. The Company recognized marketing and advertising costs as follows: Schedule of marketing and advertising costs <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">98,255</td><td style="width: 1%; text-align: left; padding-bottom: 2.5pt"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">40,737</td><td style="width: 1%; text-align: left; padding-bottom: 2.5pt"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">164,920</td><td style="width: 1%; text-align: left; padding-bottom: 2.5pt"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">125,285</td><td style="width: 1%; text-align: left; padding-bottom: 2.5pt"> </td></tr> </table> Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation. Compensation cost is measured at the grant-date fair value of the award and is recognized over the requisite service period (generally the vesting period) on a straight-line basis. The guidance applies to share-based payment awards granted to both employees and non-employees. Pursuant to ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, awards granted to non-employees are accounted for in substantially the same manner as awards granted to employees, with fair value determined on the grant date. The Company estimates the fair value of stock options granted using the Black-Scholes option-pricing model. The model incorporates the following key assumptions: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Expected dividend yield - Based on the Company’s anticipated dividend policy over the expected life of the option (generally assumed to be zero, as the Company does not currently pay dividends).</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Expected volatility - Based on the historical volatility of the Company.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Risk-free interest rate - Based on the yield on U.S. Treasury securities with maturities approximating the expected term of the option.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Expected term - Estimated based on historical exercise behavior, contractual terms, and the simplified method (average of contractual term and vesting period) where appropriate.</td></tr></table> The Company has elected the practical expedient under ASU 2016-09 to account for forfeitures as they occur rather than estimating them in advance. This election is applied consistently to all stock-based awards. Stock-based compensation expense is classified in the statements of operations as a component of general and administrative expenses. In addition, the Company applies the provisions of ASU 2016-09 related to the recognition of all excess tax benefits and tax deficiencies in income tax expense in the period in which they occur and the classification of cash paid for tax withholdings on behalf of employees as financing activities in the statement of cash flows. Stock Warrants In connection with certain financing transactions (debt or equity), consulting arrangements, or strategic partnerships, the Company may issue warrants to purchase shares of its common stock. Warrants that do not meet liability classification under ASC 480, “Distinguishing Liabilities from Equity”, are evaluated under ASC 815-40, “Contracts in Entity’s Own Equity”. The Company’s outstanding warrants are not puttable or mandatorily redeemable, do not require net cash settlement, and are indexed to the Company’s own common stock. Accordingly, they are classified as equity instruments in additional paid-in capital. The fair value of warrants issued for compensation purposes is measured using the Black-Scholes option pricing model. Accounting Treatment of Warrants <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Warrants issued in conjunction with common stock issuance are initially recorded at fair value as a reduction in Additional Paid-In Capital (APIC).</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Warrants issued for services are recorded at fair value and expensed over the requisite service period or immediately upon issuance if no service period exists.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Warrants classified as liabilities due to settlement features or pricing adjustments are remeasured at fair value each reporting period, with changes recognized in earnings.</td></tr></table> Basic and Diluted Earnings (Loss) per Share The Company computes net loss per share in accordance with ASC 260, “Earnings Per Share.” Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. During all periods presented, the Company reported a net loss. Accordingly, all potentially dilutive common stock equivalents were excluded from the computation of diluted net loss per share because their inclusion would have been anti-dilutive. As a result, diluted net loss per share is equal to basic net loss per share for all periods presented. The following potentially dilutive equity securities outstanding as of June 30, 2026 and 2025 were as follows: Schedule of potentially dilutive equity securities outstanding <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%; text-align: left">Stock Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--TotalCommonStockEquivalents_pid_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zFnTWMeT1Uzf" style="width: 16%; text-align: right" title="Stock Options">5,150,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--TotalCommonStockEquivalents_pid_uShares_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zfc2BaNOY66j" style="width: 16%; text-align: right" title="Stock Options">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--TotalCommonStockEquivalents_pid_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKCNyEy8rrN" style="text-align: right" title="Warrants">2,100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--TotalCommonStockEquivalents_pid_uShares_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFoTxZggPBq5" style="text-align: right" title="Warrants">2,100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series A, convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--TotalCommonStockEquivalents_pid_uShares_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zNKonTcceu63" style="text-align: right" title="Series A, convertible preferred stock">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--TotalCommonStockEquivalents_pid_uShares_c20250101__20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuq6XmNgds21" style="text-align: right" title="Series A, convertible preferred stock">1,088</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Series B, convertible preferred stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--TotalCommonStockEquivalents_pid_uShares_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zAunSlcQAkT3" style="border-bottom: Black 1pt solid; text-align: right" title="Series B, convertible preferred stock">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--TotalCommonStockEquivalents_pid_uShares_c20250101__20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z1zOnFotqaW5" style="border-bottom: Black 1pt solid; text-align: right" title="Series B, convertible preferred stock">48,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total common stock equivalents</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--TotalCommonStockEquivalents_c20260101__20260630_zkjAJgIshbf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total common stock equivalents">7,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_ecustom--TotalCommonStockEquivalents_c20250101__20250630_zpJm8qCSM77h" style="border-bottom: Black 2.5pt double; text-align: right" title="Total common stock equivalents">2,149,088</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Based on the potential common stock equivalents noted above at June 30, 2026, the Company has sufficient authorized shares of common stock (100,000,000) to settle any potential exercises of common stock equivalents. Preferred Stock Classification The Company applies the guidance outlined in ASC 480, “Distinguishing Liabilities from Equity”, in determining the appropriate classification and measurement of preferred stock. Under FASB ASC 480-10-25-4, financial instruments that embody an obligation to repurchase equity shares or require mandatory redemption at a fixed or determinable date must be classified as a liability and measured at fair value. Preferred shares that are conditionally redeemable - including those redeemable at the option of the holder or subject to redemption upon the occurrence of events outside the issuer’s control - are classified as temporary equity in accordance with FASB ASC 480-10-S99-3A. Conversely, preferred shares that are not mandatorily redeemable and whose redemption rights are within the issuer’s control are appropriately classified as a component of stockholders’ equity. Related Parties The Company defines related parties in accordance with FASB ASC 850, “Related Party Disclosures,” and SEC Regulation S-X, Rule 4-08(k). Related parties include entities and individuals that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties include, but are not limited to: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Principal owners of the Company.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Members of management (including directors, executive officers, and key employees).</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Immediate family members of principal owners and members of management.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Entities affiliated with principal owners or management through direct or indirect ownership.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Entities with which the Company has significant transactions, where one party has the ability to exercise control or significant influence over the management or operating policies of the other.</td></tr></table> A party is considered related if it has the ability to control or significantly influence the management or operating policies of the Company in a manner that could prevent either party from fully pursuing its own separate economic interests. The Company discloses all material related party transactions, including: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">The nature of the relationship between the parties.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">A description of the transaction(s), including terms and amounts involved.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Any amounts due to or from related parties as of the reporting date.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Any other elements necessary for a clear understanding of the transactions’ effects on the financial statements.</td></tr></table> Disclosures are made in accordance with FASB ASC 850-10-50-1 through 50-6 and SEC Regulation S-X, Rule 4-08(k), which requires registrants to disclose material related party transactions and their effects on the financial position and results of operations. See Note 5 for related party debt. Recent Accounting Standards Recently Adopted Accounting Standards FASB ASU 2023-07 - Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In November 2023, the FASB issued ASU 2023-07, which enhances reportable segment disclosure requirements by: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Requiring disclosure of significant segment expenses regularly provided to the chief operating decision maker (CODM);</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Requiring disclosure of the title and position of the CODM;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Extending certain annual disclosures to interim periods; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Clarifying that single reportable segment entities must apply ASC 280 in its entirety.</td></tr></table> ASU 2023-07 is effective for annual periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024, with retrospective application required. The Company adopted ASU 2023-07 for its annual reporting period ended December 31, 2024, and for interim periods beginning January 1, 2025. The adoption resulted in enhanced segment disclosures but did not have a material impact on the Company’s financial position, results of operations, or cash flows. FASB ASU 2023-09 - Income Taxes (Topic 740): Improvements to Income Tax Disclosures In December 2023, the FASB issued ASU 2023-09, which enhances income tax disclosure requirements by: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Standardizing and disaggregating rate reconciliation categories; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Requiring disclosure of income taxes paid by jurisdiction.</td></tr></table> ASU 2023-09 is effective for annual periods beginning after December 15, 2024, and may be applied on a prospective or retrospective basis. The Company adopted ASU 2023-09 effective January 1, 2025. The adoption resulted in enhanced income tax disclosures but did not have a material impact on the Company’s financial position, results of operations, or cash flows. FASB ASU 2025-05 - Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets In July 2025, the FASB issued ASU 2025-05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The ASU provides a practical expedient that permits entities to assume that current economic conditions as of the balance sheet date will remain unchanged over the remaining life of current (short-term) accounts receivable and current contract assets arising from transactions accounted for under ASC 606. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025, and interim periods within those fiscal years, with early adoption permitted in both interim and annual reporting periods in which financial statements have not yet been issued or made available for issuance. The amendments are required to be applied prospectively. The Company early adopted ASU 2025-05 effective January 1, 2025 and elected the practical expedient. The adoption did not have a material impact on the Company’s financial position, results of operations, or cash flows. FASB ASU 2024-04 - Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments In November 2024, the FASB issued ASU 2024-04, which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. The amendments also clarify that the incorporation, elimination, or modification of a volume-weighted average price (VWAP) formula does not automatically result in an extinguishment. ASU 2024-04 is effective for annual periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Adoption may be applied on a prospective or retrospective basis. The Company adopted ASU 2024-04 effective January 1, 2026. The adoption did not have a material impact on the Company’s financial position, results of operations, or cash flows. Recently Issued Accounting Standards Not Yet Adopted FASB ASU 2024-03 / ASU 2025-01 - Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation Disclosures In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which requires public business entities to disclose, in annual and interim reporting periods, disaggregated information about certain income statement expense line items in a tabular format, along with a qualitative reconciliation to the captions on the face of the financial statements. In January 2025, the FASB issued ASU 2025-01 to clarify that the effective date for non-calendar year-end entities requires initial adoption in an annual reporting period, not an interim period. The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and may be applied on either a prospective or retrospective basis. The Company is currently assessing the potential impact of ASU 2024-03 / ASU 2025-01 on its financial statement disclosures. Other Accounting Standards Updates The Company has evaluated all other recently issued accounting standards not yet effective and has determined that the adoption of such standards is not expected to have a material impact on the Company’s financial statements or disclosures. The FASB has also issued various technical corrections and industry-specific updates that are not expected to have a material impact on the Company’s financial position, results of operations, or cash flows.

Business Segments and Expense Disclosure The Company follows Financial Accounting Standards Board (FASB) ASC 280, Segment Reporting, which requires public entities to report financial and descriptive information about their reportable operating segments. FASB ASC 280-10-50-1 states that an operating segment is a component of a public entity that: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Engages in business activities from which it may earn revenues and incur expenses;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Has operating results that are regularly reviewed by the Chief Operating Decision Maker (CODM), who is the Company’s Chief Executive Officer, to make decisions about resource allocation and performance assessment; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Has discrete financial information available.</td></tr></table> Under ASC 280-10-50-10, a public entity is required to report separately only those operating segments that meet certain quantitative thresholds. However, as specified in FASB ASC 280-10-50-11, if a company’s business activities are managed as a single operating segment and reviewed on a basis, the company may report as a single segment. The Company has determined that it operates as one reportable segment, as its CODM reviews the business as a whole rather than by distinct business components. Significant expenses within loss from operations, as well as within net loss, include cost of sales and general and administrative expenses, which are each presented separately on the accompanying Statements of Operations. Other segment items within net loss include interest expense, net, and amortization of debt discount. In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which requires all public entities, including public entities with a single reportable segment, to provide in interim and annual periods one or more measures of segment profit or loss used by the chief operating decision maker to allocate resources and assess performance. Additionally, the standard requires disclosures of significant segment expenses and other segment items as well as incremental qualitative disclosures. The Company adopted ASU 2023-07 for its annual reporting period ended December 31, 2024 and for interim periods beginning January 1, 2025, on a retrospective basis. The adoption did not change the way the Company identifies its reportable segments and, accordingly, did not have a material impact on the Company’s segment-related disclosures. The adoption of 2023-07 did not change the way that the Company identifies its reportable segments and, as a result, did not have a material impact on the Company’s segment-related disclosures.

Use of Estimates and Assumptions The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the recognition of revenues and expenses during the reporting period. Actual results may differ from these estimates, and such differences could be material. Changes in estimates are recorded in the period in which they become known and are accounted for prospectively. The Company bases its estimates on historical experience, industry trends, and other relevant factors, incorporating both quantitative and qualitative assessments that it believes are reasonable under the circumstances. Significant estimates during the six months ended June 30, 2026 and 2025 include: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Allowance for doubtful accounts and other receivables </td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Inventory reserves and classifications </td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Valuation of equity based instruments </td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Estimated useful lives of property and equipment </td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Implicit interest rate in right-of-use operating leases </td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Uncertain tax positions </td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Valuation allowance on deferred tax assets </td></tr></table>

Risks and Uncertainties The Company operates in a highly competitive industry that is subject to intense market dynamics, shifting consumer demand, and economic fluctuations. The Company’s operations are exposed to significant financial, operational, and strategic risks, including potential business disruptions, supply chain constraints, and liquidity challenges. In accordance with FASB ASC 275, “Risks and Uncertainties,” the Company evaluates and discloses risks that could materially affect its financial condition, results of operations, and business outlook. Key factors contributing to variability in sales and earnings include: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">1.</td><td style="text-align: justify">Industry Cyclicality – The Company’s financial performance is affected by industry trends, seasonality, and shifts in market demand.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">2.</td><td style="text-align: justify">Macroeconomic Conditions– Economic downturns, inflationary pressures, interest rate changes, global tariff policy, and geopolitical risks may impact consumer purchasing behavior and the Company’s revenue streams.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">3.</td><td style="text-align: justify">Pricing Volatility– The cost and availability of raw materials, supply chain disruptions, and competitive pricing pressures can lead to fluctuations in gross margins and profitability.</td></tr></table> Given these uncertainties, the Company faces challenges in accurately forecasting financial performance and may experience material risks affecting liquidity, business continuity, and long-term strategic growth. The Company continuously assesses these risks and implements measures to mitigate their potential impact.

Fair Value of Financial Instruments The Company accounts for financial instruments in accordance with Financial Accounting Standards Board (FASB) ASC 820, “Fair Value Measurements”, which establishes a framework for measuring fair value and requires related disclosures. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the Company’s principal market or, if none exists, the most advantageous market for the asset or liability. Fair Value Hierarchy FASB ASC 820 requires the use of observable inputs whenever available and establishes a three-tier hierarchy for measuring fair value: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Level 1 – Quoted market prices (unadjusted) for identical assets or liabilities in active markets.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Level 2 – Observable inputs other than quoted prices in active markets, such as quoted prices for similar assets and liabilities or inputs that are directly or indirectly observable.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Level 3 – Unobservable inputs that require significant judgment, including management assumptions and estimates based on available market data.</td></tr></table> The classification of an asset or liability within the hierarchy is based on the lowest level of input that is significant to the fair value measurement. Level 3 valuations generally require more judgment and complexity, often involving a combination of cost, market, or income approaches, as well as assumptions about market conditions, pricing, and other factors. Fair Value Determination The Company assesses the fair value of its financial instruments and, where appropriate, may engage external valuation specialists to assist in determining fair value. While management believes that recorded fair values are reasonable, they may not necessarily reflect net realizable values or future fair values. Financial Instruments Carried at Historical Cost The Company’s financial instruments—including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses (including related party balances)—are recorded at historical cost. As of June 30, 2026 and December 31, 2025, respectively, the carrying amounts of these instruments approximated their fair values due to their short-term maturities.

Cash and Cash Equivalents and Concentration of Credit Risk For purposes of the statements of cash flows, the Company considers all highly liquid investments with original maturities of three months or less from the date of purchase, including money market accounts and short-term certificates of deposit, to be cash equivalents. At June 30, 2026, the Company did not hold any cash equivalents At December 31, 2025, the Company’s cash equivalents consisted of a money market account. The Company is exposed to credit risk on its cash and cash equivalents in the event of default by the financial institutions to the extent account balances exceed the amount insured by the FDIC, which is $250,000. At June 30, 2026 and December 31, 2025, the Company had cash in excess of the insured FDIC limit of $112,178 and $2,272,502, respectively. From time to time the Company has amounts that exceed the FDIC insured amount but does not expect any non-performance.

250000

112178

2272502

Accounts Receivable The Company accounts for accounts receivable in accordance with FASB ASC 326, “Financial Instruments – Credit Losses. Receivables are recorded at their net realizable value, which represents the amount management expects to collect from outstanding customer balances. The Company extends credit to customers based on an evaluation of their financial condition and other factors. The Company does not require collateral, and interest is not accrued on overdue accounts receivable. Allowance for Expected Credit Losses The Company has elected the practical expedient in Accounting Standards Update (ASU) 2025-05 for its current (short-term) accounts receivable. Under this practical expedient, the Company assumes that current economic conditions as of the balance sheet date will not change over the remaining life of these receivables when estimating expected credit losses. Management periodically assesses the collectability of accounts receivable and establishes an allowance for expected credit losses as needed. The allowance is determined based on: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">A review of outstanding accounts,</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Historical collection experience, and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Current economic conditions.</td></tr></table> Accounts deemed uncollectible are written off against the allowance when determined to be uncollectible. Allowance for expected credit losses was $0 at June 30, 2026 and December 31, 2025, respectively.

0 0

Inventory Inventory consists of scanning equipment and is stated at the lower of cost or net realizable value (“LCNRV”) using the first-in, first-out (“FIFO”) method. Management assesses the recoverability of inventory each reporting period and records write-downs to net realizable value when the carrying value exceeds estimated proceeds from sale, less costs to complete and sell. Factors considered in this assessment include: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Market conditions;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Net realizable value based on estimated selling price and selling costs; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Inventory turnover trends.</td></tr></table> During the year ended December 31, 2025, the Company recorded an inventory write-down of $576,862 (included in cost of sales) to reduce the carrying value of its scanning equipment to net realizable value. Net realizable value was determined based on the estimated selling price under an existing sales contract, less estimated costs to complete and sell the equipment. A customer deposit related to this contract is recorded in deferred revenue (see the revenue recognition discussion below). During the six months ended June 30, 2026, the Company incurred $238,352 of additional equipment costs to ready the unit for sale and recorded a corresponding inventory write-down of $238,352, which is included in cost of goods sold. The machine will be delivered to the customer upon completion of installment payments under an executed sale agreement and upon FDA approval; the corresponding consideration received to date has been recorded as deferred revenue (see below). At June 30, 2026 and December 31, 2025, inventory was as follows: Schedule of Inventory <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Classification</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 62%; text-align: left">Finished systems</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_c20260630_zuOkXFt016gf" style="width: 16%; text-align: right" title="Finished systems">918,352</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_c20251231_zTKbYYH9fK98" style="width: 16%; text-align: right" title="Finished systems">1,256,862</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Less: writedown of inventory to net realizable value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--InventoryWriteDown_iN_di_c20260101__20260630_zmGGjOBcPre4" style="border-bottom: Black 1pt solid; text-align: right" title="Less: writedown of inventory to net realizable value">(238,352</td><td style="padding-bottom: 0.5pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--InventoryWriteDown_iN_di_c20250101__20251231_zWUTno3Jtz6" style="border-bottom: Black 1pt solid; text-align: right" title="Less: writedown of inventory to net realizable value">(576,862</td><td style="padding-bottom: 0.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Total Inventory</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--InventoryNet_iI_c20260630_zcGyjiBt9jO5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Inventory">680,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--InventoryNet_iI_c20251231_zmZtdPe06lV8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Inventory">680,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

576862

238352

At June 30, 2026 and December 31, 2025, inventory was as follows: Schedule of Inventory <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Classification</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 62%; text-align: left">Finished systems</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_c20260630_zuOkXFt016gf" style="width: 16%; text-align: right" title="Finished systems">918,352</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_c20251231_zTKbYYH9fK98" style="width: 16%; text-align: right" title="Finished systems">1,256,862</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Less: writedown of inventory to net realizable value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--InventoryWriteDown_iN_di_c20260101__20260630_zmGGjOBcPre4" style="border-bottom: Black 1pt solid; text-align: right" title="Less: writedown of inventory to net realizable value">(238,352</td><td style="padding-bottom: 0.5pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--InventoryWriteDown_iN_di_c20250101__20251231_zWUTno3Jtz6" style="border-bottom: Black 1pt solid; text-align: right" title="Less: writedown of inventory to net realizable value">(576,862</td><td style="padding-bottom: 0.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Total Inventory</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--InventoryNet_iI_c20260630_zcGyjiBt9jO5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Inventory">680,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--InventoryNet_iI_c20251231_zmZtdPe06lV8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Inventory">680,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

918352

1256862

238352

576862

680000

Deposits Deposits represent amounts paid to a third-party manufacturer toward the purchase of a PET-CT system, the recoverability of which is contingent upon successful equipment validation and U.S. Food and Drug Administration (FDA) clearance. Activity in deposits for the six months ended June 30, 2026 and the year ended December 31, 2025 was as follows: Schedule of Deposits <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td style="width: 42%; text-align: left">December 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Deposits_iS_c20250101__20251231_zusvzQ62rbL2" style="width: 5%; text-align: right" title="Deposits Beginning">375,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">No activity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--DepositsActivity_c20250101__20251231_zRxn8lY6ZVul" style="text-align: right" title="No activity">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">December 31, 2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--Deposits_iS_c20260101__20260630_zuaIBn12wECi" style="text-align: right" title="Deposits Beginning">375,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">No activity</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--DepositsActivity_c20260101__20260630_zliFbwMgPSDd" style="border-bottom: Black 1pt solid; text-align: right" title="No activity">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--Deposits_iE_c20260101__20260630_zMNvkGVazZ9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Deposits Ending">375,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> In 2022, the Company paid $1,000,000 for equipment from its manufacturing partner, Neusoft Medical Systems, In connection with the same transaction, the Company agreed to pay a Non-Recurring Engineering (NRE) Fee of $700,000 to the manufacturer for research, development, and technology transfer services, payable as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">$210,000 paid in 2022; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">$490,000 paid in 2025.</td></tr></table> Because the equipment has not received FDA clearance, the $<span id="xdx_906_eus-gaap--GeneralAndAdministrativeExpense_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zUsa8LxaomU1" title="General and Administrative Expense">490,000 paid in 2025 was charged to general and administrative expense in the accompanying statements of operations for the year ended December 31, 2025. If the equipment fails validation or does not receive FDA clearance, the Company has the contractual right to return the inventory and obtain a refund of the $1,000,000 purchase price, less applicable shipping and handling costs. The manufacturer has also agreed to provide a one-year warranty on the equipment and related software, commencing upon closing of the equipment purchase. Deposits represent amounts paid to a third-party manufacturer toward the purchase of a PET-CT system, the recoverability of which is contingent upon successful equipment validation and U.S. Food and Drug Administration (FDA) clearance. Activity in deposits for the six months ended June 30, 2026 and the year ended December 31, 2025 was as follows: Schedule of Deposits <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td style="width: 42%; text-align: left">December 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Deposits_iS_c20250101__20251231_zusvzQ62rbL2" style="width: 5%; text-align: right" title="Deposits Beginning">375,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">No activity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--DepositsActivity_c20250101__20251231_zRxn8lY6ZVul" style="text-align: right" title="No activity">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">December 31, 2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--Deposits_iS_c20260101__20260630_zuaIBn12wECi" style="text-align: right" title="Deposits Beginning">375,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">No activity</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--DepositsActivity_c20260101__20260630_zliFbwMgPSDd" style="border-bottom: Black 1pt solid; text-align: right" title="No activity">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--Deposits_iE_c20260101__20260630_zMNvkGVazZ9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Deposits Ending">375,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

375000

1000000

210000

490000

1000000

Concentrations The Company evaluates and discloses significant concentrations of risk in accordance with FASB ASC 275-10, “Risks and Uncertainties”. These risks may arise from customer concentrations, vendor reliance, geographic dependence, or other economic factors that could materially impact the Company’s financial position, results of operations, and cash flows. A concentration exists when a single customer, supplier, or market accounts for a significant portion (typically greater than 10%) of the Company’s total revenues, accounts receivable, or vendor purchases For the six months ended June 30, 2026 and 2025, respectively, the Company has no such concentrations.

Property and Equipment Property and equipment are recorded at cost, net of accumulated depreciation, in accordance with FASB ASC 360, “Property, Plant, and Equipment.” Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance expenditures that do not materially extend the useful life of an asset are expensed as incurred. Significant improvements or upgrades that increase the asset’s productivity, efficiency, or useful life are capitalized. Upon disposal or sale of property and equipment, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in the statement of operations. The Company evaluates the carrying value of property and equipment whenever events or changes in circumstances indicate that the asset may be impaired. If impairment indicators exist, the Company assesses recoverability based on the undiscounted future cash flows expected from the use and disposition of the asset. If the carrying amount exceeds the estimated recoverable amount, an impairment loss is recognized.

<p id="xdx_84A_ecustom--FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyTextBlock_zbJgbvvgtBnj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Financial Instruments with Characteristics of Both Liabilities and Equity The Company evaluates equity or liability classification for freestanding financial instruments, including convertible preferred stock, warrants, and options, pursuant to the guidance under FASB ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”). The Company classifies as liabilities all freestanding financial instruments that are (i) mandatorily redeemable, (ii) represent an obligation to repurchase the Company’s equity shares by transferring assets, or (iii) represent an unconditional obligation (or conditional obligation if the financial instrument is not an outstanding share) to issue a variable number of shares predominantly based on a fixed monetary amount, variations in something other than the fair value of the Company’s equity shares, or variations inversely related to changes in fair value of the Company’s equity shares. If a freestanding financial instrument does not represent an outstanding equity share and does not meet liability classification under ASC 480, the Company then assesses whether the freestanding financial instrument is indexed to its own stock and meets equity classification pursuant to FASB ASC 815-40, “Contracts in Entity’s Own Equity” (“ASC 815”). The Company further assesses whether the freestanding financial instruments should be classified as temporary equity. Freestanding financial instruments that are redeemable for cash or other assets at a fixed or determinable date, at the option of the holder, or upon the occurrence of an event are classified in temporary equity in accordance with FASB ASC 480. Otherwise, the freestanding financial instruments are classified in permanent equity. Conversion and Extinguishment of Derivative Liabilities When a debt instrument with an embedded conversion option (e.g., convertible debt or warrants) is converted into shares of common stock or repaid, the Company: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Records the newly issued shares at fair value;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Derecognizes all related debt, derivative liabilities, and unamortized debt discounts; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Recognizes a gain or loss on debt extinguishment, if applicable.</td></tr></table> For equity-based derivative liabilities (e.g., warrants) that are extinguished, any remaining liability balance is reclassified to additional paid-in capital. <p id="xdx_840_ecustom--OriginalIssueDiscountsAndOtherDebtDiscountsPolicyTextBlock_zcWdWNQR9Fia" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Original Issue Discounts and Other Debt Discounts The Company accounts for original issue discounts (OID) and other debt discounts in accordance with FASB ASC 835-30, “Interest—Imputation of Interest”. These discounts are recorded as a reduction of the carrying amount of the related debt and are amortized to interest expense over the term of the debt using the effective interest method, unless the straight-line method is materially similar. Original Issue Discounts (OID) For certain notes issued, the Company may provide the debt holder with an original issue discount (OID), which is recorded as a debt discount, reducing the face value of the note. The discount is amortized to interest expense over the term of the debt in the Statements of Operations. Stock and Other Equity Issued with Debt The Company may issue common stock or other equity instruments in connection with debt issuance. When stock is issued, it is recorded at relative fair value and treated as a debt discount, reducing the carrying amount of the note. These discounts are amortized to interest expense over the life of the debt. The combined debt discounts, including OID and stock-related discounts, cannot exceed the face amount of the debt. Debt Issuance Costs Debt issuance costs, including fees paid to lenders or third parties, are capitalized as a debt discount and amortized to interest expense over the life of the debt. These costs are presented as a direct deduction from the carrying amount of the debt liability rather than as a separate asset. Warranties and Maintenance Contracts Product Warranties The Company provides an assurance-type warranty on its products covering defects in design, materials, and workmanship for a period of one year from customer acceptance. Assurance-type warranties do not represent a separate performance obligation under ASC 606; rather, the estimated cost of fulfilling the warranty obligation is accrued at the time of product delivery in accordance with ASC 460-10-25-5 and ASC 450-20-25, when the obligation is probable and reasonably estimable. The warranty provision is based on historical trends in defect nature, frequency, and average cost of claims for each product line. These estimates are reassessed each reporting period using the best available information, and adjustments are made as necessary. Historically, the Company has incurred insignificant warranty-related costs. At June 30, 2026 and December 31, 2025, no warranty liability was recorded, as the estimated obligation was deemed immaterial. Certain components used in the Company’s products are covered under supplier-provided limited warranties, which include replacement and service coverage for parts. The Company does not have direct responsibility for these supplier warranties. As of June 30, 2026 and December 31, 2025, the Company is not aware of any pending or asserted claims related to product warranty obligations. Maintenance Contracts The Company separately offers post-delivery maintenance contracts to customers. Maintenance contracts are distinct from the Company’s assurance-type product warranty and represent separate performance obligations under ASC 606. Revenue attributable to maintenance contracts is deferred at contract inception and recognized ratably over the maintenance period as the related services are performed. At June 30, 2026 and December 31, 2025, no maintenance contract revenue was deferred. Treasury Stock The Company accounts for treasury stock transactions under the cost method in accordance with FASB ASC 505-30, “Treasury Stock”. Under this method, when the Company repurchases its own shares, the full acquisition cost is recorded as a reduction to stockholders’ equity under the treasury stock account. These shares remain issued but are not considered outstanding and do not participate in dividends or earnings per share calculations. As of June 30, 2026 and December 31, 2025, respectively, the Company had 750 shares of treasury stock recorded at an aggregate cost of $375.

750

375

Right of Use Assets and Lease Obligations The Company accounts for right-of-use (ROU) assets and lease liabilities in accordance with FASB ASC 842, “Leases”. These amounts reflect the present value of the Company’s estimated future minimum lease payments over the lease term, including any reasonably certain renewal options, discounted using a collateralized incremental borrowing rate. The Company classifies its leases as either operating or finance leases. The Company’s leases primarily consist of operating leases, which are included as Right-of-Use Assets and Operating Lease Liabilities on the balance sheet. Short-Term Leases The Company has elected the short-term lease exemption, whereby leases with a term of 12 months or less are not recorded on the balance sheet. Instead, lease payments are expensed on a straight-line basis over the lease term. Lease Term and Renewal Options In determining the lease term, the Company evaluates whether renewal options are reasonably certain to be exercised. Factors considered include: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">The useful life of leasehold improvements relative to the lease term,</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">The economic performance of the business at the leased location,</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">The comparative cost of renewal rates versus market rates, and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">The presence of any significant economic penalties for non-renewal.</td></tr></table> If a renewal option is deemed reasonably certain to be exercised, the ROU asset and lease liability reflect those additional future lease payments. The Company’s operating leases contain renewal options with no residual value guarantees. Currently, management does not expect to exercise any renewal options, which are therefore excluded in the measurement of lease obligations. Discount Rate and Lease Liability Measurement Since the implicit rate in the leases is not readily determinable, the Company applies an incremental borrowing rate that represents the rate it would incur to borrow on a collateralized basis over a similar term and currency environment. Lease Impairment The Company evaluates ROU assets for impairment indicators whenever events or changes in circumstances suggest the carrying amount may not be recoverable. See Note 6 for further discussion on lease cancellation during the year December 31, 2025.

Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized when or as control of promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, performance obligations are satisfied. Nature of Services and Performance Obligations The Company generates revenue primarily from clinical, technical, and maintenance service contracts that provide customers with ongoing product support and from sales of equipment. These contracts are generally one-year agreements that automatically renew for successive one-year periods unless terminated by either party with at least 90 days’ notice. The Company considers only the noncancelable initial term and any renewal periods for which the customer has a material right when determining the contract term and performance obligations. Each maintenance contract represents a single distinct performance obligation. The various service elements - including priority response, 24/7 clinical and technical support, parts and labor, preventative maintenance, software upgrades, uptime guarantees, remote diagnostic capabilities, daily quality assurance inspections, and applications training - are highly integrated and interdependent. They are not separately identifiable from one another and are accounted for as a single stand-ready performance obligation that is satisfied continuously over the contract term. Significant Judgments In applying ASC 606, the Company makes the following significant judgments that affect the timing and amount of revenue recognized: (i) the Company concluded that all services under each maintenance contract constitute a single performance obligation because they are highly interrelated and provide a combined integrated service to the customer; (ii) for maintenance contracts, the Company uses a time-based, straight-line output method to measure progress, which it has determined faithfully depicts the Company’s performance as the customer simultaneously receives and consumes the benefits of the services; and (iii) for equipment sales, the Company applies judgment in assessing when control transfers to the customer. No changes to these judgments have occurred during the periods presented. Transaction Price and Allocation The transaction price is the fixed fee stated in each contract. The Company does not offer refunds, rebates, discounts, or variable pricing incentives. Maintenance contract fees are typically billed monthly in advance with payment due within 30 days. As permitted by the practical expedient in ASC 606-10-32-18, the Company does not adjust the transaction price for the effects of a significant financing component when the period between transfer of control of the good or service and customer payment is one year or less. Because each contract contains a single performance obligation, the entire transaction price is allocated to that obligation. Revenue Recognition – Timing The Company recognizes revenue either over time or at a point in time depending on the nature of the performance obligation. Maintenance contract revenue is recognized over time as the customer simultaneously receives and consumes the benefits of the services as they are provided. Revenue is recognized ratably on a straight-line basis over the contract term. Amounts received in advance of services being provided are recorded as deferred revenue and recognized as revenue as the related performance obligations are satisfied. Equipment sale revenue is recognized at a point in time when control of the equipment transfers to the customer, which occurs upon physical delivery and acceptance of the equipment and where collection is probable. In the three and six months ended June 30, 2026 and 2025, no equipment sale revenue had been recognized, as the conditions for transfer of control had not yet been met. Principal vs. Agent Considerations The Company has determined that it acts as a principal in all revenue transactions. The Company controls the services prior to transfer to the customer, is responsible for fulfilling all contractual obligations including uptime guarantees, bears the risk of performance, and has discretion in establishing contract pricing. Accordingly, revenue is recognized on a gross basis. Contract Balances and Remaining Performance Obligations The Company’s contract liabilities consist of deferred revenue related to maintenance contracts billed in advance and customer deposits on pending equipment sales. These amounts are presented as deferred revenue on the accompanying balance sheets. There were no contract assets as of June 30, 2026 or December 31, 2025. The Company has elected the practical expedient under ASC 606-10-50-14 not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for contracts with an original expected duration of one year or less. Disaggregation of Revenue The following table presents the Company’s revenues disaggregated by type for the six months ended June 30, 2026 and 2025: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>Schedule of Company’s revenues disaggregated</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Sales</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center"> Revenue </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% of Revenues</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center"> Revenue </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% of Revenues</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 40%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Service Income</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_c20260401__20260630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_zW7i7V7qjyd3" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">111,822</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--RevenuesPercentage_pid_dp_uRatio_c20260401__20260630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_zhFAlZfD4xvb" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--Revenues_c20250401__20250630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_zxVMi1S9E5R7" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">120,118</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--RevenuesPercentage_pid_dp_uRatio_c20250401__20250630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_z6aiO33nWGJc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20260401__20260630_zsoxOmh5uRtl" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">111,822</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_ecustom--RevenuesPercentage_pid_dp_uRatio_c20260401__20260630_z7rhIzD7XsEe" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--Revenues_c20250401__20250630_z0Zuum7rYzee" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">120,118</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--RevenuesPercentage_pid_dp_uRatio_c20250401__20250630_zdkGQiAk4AUe" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> Schedule of Company’s revenues disaggregated <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Sales</td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"> Revenue </td><td style="padding-bottom: 1pt; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% of Revenues</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center"> Revenue </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% of Revenues</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 40%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Service Income</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20260101__20260630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_z4hrr0gqSMDh" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">222,822</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--RevenuesPercentage_pid_dp_uRatio_c20260101__20260630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_zy9e4AWIYGp9" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20250101__20250630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_zYT8EiHEM8B5" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">239,452</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--RevenuesPercentage_pid_dp_uRatio_c20250101__20250630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_zZHL2UeLRjwj" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20260101__20260630_zcUDtjvbaY73" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">222,822</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_ecustom--RevenuesPercentage_pid_dp_uRatio_c20260101__20260630_ztjSFOeP1XYd" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_c20250101__20250630_zGjm83vi2Yfh" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">239,452</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--RevenuesPercentage_pid_dp_uRatio_c20250101__20250630_zifcfM8elpx2" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> All revenue recognized in both periods was derived from maintenance service contracts. No equipment sale revenue has been recognized in either period, as transfer of control of the equipment to the customer had not yet occurred as of each respective balance sheet date.

The following table presents the Company’s revenues disaggregated by type for the six months ended June 30, 2026 and 2025: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>Schedule of Company’s revenues disaggregated</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Sales</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center"> Revenue </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% of Revenues</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center"> Revenue </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% of Revenues</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 40%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Service Income</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_c20260401__20260630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_zW7i7V7qjyd3" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">111,822</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--RevenuesPercentage_pid_dp_uRatio_c20260401__20260630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_zhFAlZfD4xvb" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--Revenues_c20250401__20250630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_zxVMi1S9E5R7" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">120,118</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--RevenuesPercentage_pid_dp_uRatio_c20250401__20250630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_z6aiO33nWGJc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20260401__20260630_zsoxOmh5uRtl" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">111,822</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_ecustom--RevenuesPercentage_pid_dp_uRatio_c20260401__20260630_z7rhIzD7XsEe" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--Revenues_c20250401__20250630_z0Zuum7rYzee" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">120,118</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--RevenuesPercentage_pid_dp_uRatio_c20250401__20250630_zdkGQiAk4AUe" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> Schedule of Company’s revenues disaggregated <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Sales</td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"> Revenue </td><td style="padding-bottom: 1pt; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% of Revenues</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center"> Revenue </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% of Revenues</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 40%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Service Income</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20260101__20260630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_z4hrr0gqSMDh" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">222,822</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--RevenuesPercentage_pid_dp_uRatio_c20260101__20260630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_zy9e4AWIYGp9" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20250101__20250630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_zYT8EiHEM8B5" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">239,452</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--RevenuesPercentage_pid_dp_uRatio_c20250101__20250630__srt--ProductOrServiceAxis__us-gaap--MaintenanceMember_zZHL2UeLRjwj" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20260101__20260630_zcUDtjvbaY73" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">222,822</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_ecustom--RevenuesPercentage_pid_dp_uRatio_c20260101__20260630_ztjSFOeP1XYd" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_c20250101__20250630_zGjm83vi2Yfh" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">239,452</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--RevenuesPercentage_pid_dp_uRatio_c20250101__20250630_zifcfM8elpx2" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues Percentage">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table>

111822

120118

111822

120118

222822

239452

222822

239452

Deferred Revenue (Contract Liabilities) Deferred revenue represents consideration received from customers prior to the satisfaction of the related performance obligation. At June 30, 2026 and December 31, 2025, deferred revenue consisted of the following: Schedule of deferred revenue <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Type</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260630_zMMM2i9pBgHc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20251231_zpLwcES9pF79" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%; text-align: left">Customer deposit - equipment sale</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DeferredRevenue_iI_c20260630__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_zdwz5EQmFHlf" style="width: 16%; text-align: right" title="Deferred Revenue">210,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredRevenue_iI_c20251231__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_zeF1stfCdgb" style="width: 16%; text-align: right" title="Deferred Revenue">70,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Customer deposit - other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DeferredRevenue_iI_c20260630__srt--ProductOrServiceAxis__custom--OtherMember_zM6cElrZveL1" style="border-bottom: Black 1pt solid; text-align: right" title="Deferred Revenue">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--DeferredRevenue_iI_c20251231__srt--ProductOrServiceAxis__custom--OtherMember_zhMA6pFfk7jb" style="border-bottom: Black 1pt solid; text-align: right" title="Deferred Revenue">50,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total deferred revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--DeferredRevenue_iI_c20260630_zTA7Mn6eqDD8" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred Revenue">210,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DeferredRevenue_iI_c20251231_zBtWAnRWe6Zd" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred Revenue">120,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Equipment sale deposits represent cumulative installment payments received from customers under executed purchase agreements for medical scanning equipment. Title and physical possession of the equipment transfer to each customer upon receipt of the full contract price, at which point revenue is recognized. During 2026, additional installment payments of $140,000 were received, bringing the aggregate cumulative balance to $210,000 at June 30, 2026. The $50,000 balance at December 31, 2025 represented a payment received from a potential customer. This deposit was refunded in full during 2026. None of the deferred revenue at December 31, 2025 was recognized as revenue during 2026. Maintenance contract amounts represent consideration received from customers prior to the applicable service period and are recognized as revenue ratably as performance obligations are satisfied over the service term. At June 30, 2026, $0 remained deferred, all of which was recognized as revenue during the quarter ended June 30, 2026.

At June 30, 2026 and December 31, 2025, deferred revenue consisted of the following: Schedule of deferred revenue <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Type</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260630_zMMM2i9pBgHc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20251231_zpLwcES9pF79" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%; text-align: left">Customer deposit - equipment sale</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DeferredRevenue_iI_c20260630__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_zdwz5EQmFHlf" style="width: 16%; text-align: right" title="Deferred Revenue">210,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredRevenue_iI_c20251231__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_zeF1stfCdgb" style="width: 16%; text-align: right" title="Deferred Revenue">70,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Customer deposit - other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DeferredRevenue_iI_c20260630__srt--ProductOrServiceAxis__custom--OtherMember_zM6cElrZveL1" style="border-bottom: Black 1pt solid; text-align: right" title="Deferred Revenue">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--DeferredRevenue_iI_c20251231__srt--ProductOrServiceAxis__custom--OtherMember_zhMA6pFfk7jb" style="border-bottom: Black 1pt solid; text-align: right" title="Deferred Revenue">50,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total deferred revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--DeferredRevenue_iI_c20260630_zTA7Mn6eqDD8" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred Revenue">210,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DeferredRevenue_iI_c20251231_zBtWAnRWe6Zd" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred Revenue">120,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

210000

70000

50000

210000

120000

140000

210000

50000

Cost of Sales Cost of sales consists of direct expenses incurred in the delivery of services related to the Company’s maintenance contracts. These costs are recognized as incurred and are directly attributable to fulfilling service obligations under customer agreements. The primary components of cost of sales include: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Salaries and Wages – Compensation, payroll taxes, and employee benefits associated with the Company’s service technicians and clinical support staff.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Job-Related Materials and Supplies – Expenses for parts, tools, software upgrades, and consumable materials required to perform maintenance and repairs.</td></tr></table> All costs included in cost of sales are directly related to the provision of contracted maintenance services and align with revenue recognition principles under FASB ASC 606. The Company continually evaluates its cost structure to optimize service delivery while maintaining contractual uptime guarantees and quality assurance standards.

Income Taxes The Company accounts for income taxes using the asset and liability method prescribed by FASB ASC 740, “Income Taxes”. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences of differences between the financial reporting and tax bases of assets and liabilities. These amounts are measured using enacted tax rates expected to apply in the periods when temporary differences reverse. The effect of a change in tax rates on deferred tax balances is recognized as income or expense in the period that includes the enactment date. Uncertain Tax Positions The Company evaluates uncertain tax positions which requires that a tax position be recognized in the financial statements only if it is more likely than not (greater than 50% likelihood) to be sustained upon examination by tax authorities. As of June 30, 2026 and 2025, the Company had no uncertain tax positions that qualified for recognition or disclosure in the financial statements. The Company also recognizes interest and penalties related to uncertain tax positions in other expense in the Statement of Operations. No interest and penalties were recorded for the six months ended June 30, 2026 and 2025.

Valuation of Deferred Tax Assets The Company’s deferred tax assets include certain future tax benefits, such as net operating losses (NOLs), tax credits, and deductible temporary differences. A valuation allowance is required if it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The Company reviews the realizability of deferred tax assets on a quarterly basis, or more frequently if circumstances warrant, considering both positive and negative evidence. Considered in Valuation Allowance Assessment The Company evaluates multiple factors in determining whether a valuation allowance is necessary, including: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Historical earnings trends (cumulative pre-tax income or losses in the most recent three-year period)</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Future financial projections, including expected taxable income based on long-term estimates of business performance and market conditions</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Statutory carryforward periods for net operating losses and other deferred tax assets</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Prudent and feasible tax planning strategies that could impact the realization of deferred tax assets</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Nature and predictability of temporary differences and the timing of their reversal</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Sensitivity of financial forecasts to external factors such as commodity prices, market demand, and operational risks</td></tr></table> While cumulative three-year losses are a strong indicator that a valuation allowance may be needed, a valuation allowance determination is not solely based on past losses—all available positive and negative evidence must be considered. Valuation Allowance Determination At June 30, 2026 and December 31, 2025, the Company recorded a full valuation allowance against its deferred tax assets, resulting in a net carrying amount of $0. This determination was based on cumulative losses in recent years and the lack of sufficient positive evidence to support the realization of deferred tax assets in the near term. The Company will continue to evaluate its valuation allowance each reporting period and will recognize deferred tax assets in the future if sufficient positive evidence emerges to support their realization. There was no income tax provision recorded for the six months ended June 30, 2026 and 2025, as the Company incurred losses in both periods and maintains a full valuation allowance against its deferred tax assets.

Advertising Costs Advertising costs are expensed as incurred. These costs are recognized as operating expenses in the period in which they are incurred and are classified within general and administrative expenses in the statements of operations. The Company does not capitalize direct-response advertising costs, as they do not meet the criteria for deferral. The Company recognized marketing and advertising costs as follows: Schedule of marketing and advertising costs <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">98,255</td><td style="width: 1%; text-align: left; padding-bottom: 2.5pt"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">40,737</td><td style="width: 1%; text-align: left; padding-bottom: 2.5pt"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">164,920</td><td style="width: 1%; text-align: left; padding-bottom: 2.5pt"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">125,285</td><td style="width: 1%; text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

The Company recognized marketing and advertising costs as follows: Schedule of marketing and advertising costs <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">98,255</td><td style="width: 1%; text-align: left; padding-bottom: 2.5pt"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">40,737</td><td style="width: 1%; text-align: left; padding-bottom: 2.5pt"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">164,920</td><td style="width: 1%; text-align: left; padding-bottom: 2.5pt"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">125,285</td><td style="width: 1%; text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

98255

40737

164920

125285

Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation. Compensation cost is measured at the grant-date fair value of the award and is recognized over the requisite service period (generally the vesting period) on a straight-line basis. The guidance applies to share-based payment awards granted to both employees and non-employees. Pursuant to ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, awards granted to non-employees are accounted for in substantially the same manner as awards granted to employees, with fair value determined on the grant date. The Company estimates the fair value of stock options granted using the Black-Scholes option-pricing model. The model incorporates the following key assumptions: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Expected dividend yield - Based on the Company’s anticipated dividend policy over the expected life of the option (generally assumed to be zero, as the Company does not currently pay dividends).</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Expected volatility - Based on the historical volatility of the Company.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Risk-free interest rate - Based on the yield on U.S. Treasury securities with maturities approximating the expected term of the option.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Expected term - Estimated based on historical exercise behavior, contractual terms, and the simplified method (average of contractual term and vesting period) where appropriate.</td></tr></table> The Company has elected the practical expedient under ASU 2016-09 to account for forfeitures as they occur rather than estimating them in advance. This election is applied consistently to all stock-based awards. Stock-based compensation expense is classified in the statements of operations as a component of general and administrative expenses. In addition, the Company applies the provisions of ASU 2016-09 related to the recognition of all excess tax benefits and tax deficiencies in income tax expense in the period in which they occur and the classification of cash paid for tax withholdings on behalf of employees as financing activities in the statement of cash flows.

Stock Warrants In connection with certain financing transactions (debt or equity), consulting arrangements, or strategic partnerships, the Company may issue warrants to purchase shares of its common stock. Warrants that do not meet liability classification under ASC 480, “Distinguishing Liabilities from Equity”, are evaluated under ASC 815-40, “Contracts in Entity’s Own Equity”. The Company’s outstanding warrants are not puttable or mandatorily redeemable, do not require net cash settlement, and are indexed to the Company’s own common stock. Accordingly, they are classified as equity instruments in additional paid-in capital. The fair value of warrants issued for compensation purposes is measured using the Black-Scholes option pricing model. Accounting Treatment of Warrants <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Warrants issued in conjunction with common stock issuance are initially recorded at fair value as a reduction in Additional Paid-In Capital (APIC).</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Warrants issued for services are recorded at fair value and expensed over the requisite service period or immediately upon issuance if no service period exists.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Warrants classified as liabilities due to settlement features or pricing adjustments are remeasured at fair value each reporting period, with changes recognized in earnings.</td></tr></table> Basic and Diluted Earnings (Loss) per Share The Company computes net loss per share in accordance with ASC 260, “Earnings Per Share.” Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. During all periods presented, the Company reported a net loss. Accordingly, all potentially dilutive common stock equivalents were excluded from the computation of diluted net loss per share because their inclusion would have been anti-dilutive. As a result, diluted net loss per share is equal to basic net loss per share for all periods presented. The following potentially dilutive equity securities outstanding as of June 30, 2026 and 2025 were as follows: Schedule of potentially dilutive equity securities outstanding <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%; text-align: left">Stock Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--TotalCommonStockEquivalents_pid_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zFnTWMeT1Uzf" style="width: 16%; text-align: right" title="Stock Options">5,150,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--TotalCommonStockEquivalents_pid_uShares_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zfc2BaNOY66j" style="width: 16%; text-align: right" title="Stock Options">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--TotalCommonStockEquivalents_pid_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKCNyEy8rrN" style="text-align: right" title="Warrants">2,100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--TotalCommonStockEquivalents_pid_uShares_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFoTxZggPBq5" style="text-align: right" title="Warrants">2,100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series A, convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--TotalCommonStockEquivalents_pid_uShares_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zNKonTcceu63" style="text-align: right" title="Series A, convertible preferred stock">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--TotalCommonStockEquivalents_pid_uShares_c20250101__20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuq6XmNgds21" style="text-align: right" title="Series A, convertible preferred stock">1,088</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Series B, convertible preferred stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--TotalCommonStockEquivalents_pid_uShares_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zAunSlcQAkT3" style="border-bottom: Black 1pt solid; text-align: right" title="Series B, convertible preferred stock">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--TotalCommonStockEquivalents_pid_uShares_c20250101__20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z1zOnFotqaW5" style="border-bottom: Black 1pt solid; text-align: right" title="Series B, convertible preferred stock">48,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total common stock equivalents</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--TotalCommonStockEquivalents_c20260101__20260630_zkjAJgIshbf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total common stock equivalents">7,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_ecustom--TotalCommonStockEquivalents_c20250101__20250630_zpJm8qCSM77h" style="border-bottom: Black 2.5pt double; text-align: right" title="Total common stock equivalents">2,149,088</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Based on the potential common stock equivalents noted above at June 30, 2026, the Company has sufficient authorized shares of common stock (100,000,000) to settle any potential exercises of common stock equivalents. The following potentially dilutive equity securities outstanding as of June 30, 2026 and 2025 were as follows: Schedule of potentially dilutive equity securities outstanding <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%; text-align: left">Stock Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--TotalCommonStockEquivalents_pid_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zFnTWMeT1Uzf" style="width: 16%; text-align: right" title="Stock Options">5,150,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--TotalCommonStockEquivalents_pid_uShares_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zfc2BaNOY66j" style="width: 16%; text-align: right" title="Stock Options">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--TotalCommonStockEquivalents_pid_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKCNyEy8rrN" style="text-align: right" title="Warrants">2,100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--TotalCommonStockEquivalents_pid_uShares_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFoTxZggPBq5" style="text-align: right" title="Warrants">2,100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series A, convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--TotalCommonStockEquivalents_pid_uShares_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zNKonTcceu63" style="text-align: right" title="Series A, convertible preferred stock">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--TotalCommonStockEquivalents_pid_uShares_c20250101__20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuq6XmNgds21" style="text-align: right" title="Series A, convertible preferred stock">1,088</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Series B, convertible preferred stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--TotalCommonStockEquivalents_pid_uShares_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zAunSlcQAkT3" style="border-bottom: Black 1pt solid; text-align: right" title="Series B, convertible preferred stock">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--TotalCommonStockEquivalents_pid_uShares_c20250101__20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z1zOnFotqaW5" style="border-bottom: Black 1pt solid; text-align: right" title="Series B, convertible preferred stock">48,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total common stock equivalents</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--TotalCommonStockEquivalents_c20260101__20260630_zkjAJgIshbf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total common stock equivalents">7,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_ecustom--TotalCommonStockEquivalents_c20250101__20250630_zpJm8qCSM77h" style="border-bottom: Black 2.5pt double; text-align: right" title="Total common stock equivalents">2,149,088</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5150000 2100000 2100000 1088 48000 7250000 2149088 Preferred Stock Classification The Company applies the guidance outlined in ASC 480, “Distinguishing Liabilities from Equity”, in determining the appropriate classification and measurement of preferred stock. Under FASB ASC 480-10-25-4, financial instruments that embody an obligation to repurchase equity shares or require mandatory redemption at a fixed or determinable date must be classified as a liability and measured at fair value. Preferred shares that are conditionally redeemable - including those redeemable at the option of the holder or subject to redemption upon the occurrence of events outside the issuer’s control - are classified as temporary equity in accordance with FASB ASC 480-10-S99-3A. Conversely, preferred shares that are not mandatorily redeemable and whose redemption rights are within the issuer’s control are appropriately classified as a component of stockholders’ equity. Related Parties The Company defines related parties in accordance with FASB ASC 850, “Related Party Disclosures,” and SEC Regulation S-X, Rule 4-08(k). Related parties include entities and individuals that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties include, but are not limited to: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Principal owners of the Company.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Members of management (including directors, executive officers, and key employees).</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Immediate family members of principal owners and members of management.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Entities affiliated with principal owners or management through direct or indirect ownership.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Entities with which the Company has significant transactions, where one party has the ability to exercise control or significant influence over the management or operating policies of the other.</td></tr></table> A party is considered related if it has the ability to control or significantly influence the management or operating policies of the Company in a manner that could prevent either party from fully pursuing its own separate economic interests. The Company discloses all material related party transactions, including: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">The nature of the relationship between the parties.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">A description of the transaction(s), including terms and amounts involved.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Any amounts due to or from related parties as of the reporting date.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Any other elements necessary for a clear understanding of the transactions’ effects on the financial statements.</td></tr></table> Disclosures are made in accordance with FASB ASC 850-10-50-1 through 50-6 and SEC Regulation S-X, Rule 4-08(k), which requires registrants to disclose material related party transactions and their effects on the financial position and results of operations. See Note 5 for related party debt.

Recent Accounting Standards Recently Adopted Accounting Standards FASB ASU 2023-07 - Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In November 2023, the FASB issued ASU 2023-07, which enhances reportable segment disclosure requirements by: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Requiring disclosure of significant segment expenses regularly provided to the chief operating decision maker (CODM);</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Requiring disclosure of the title and position of the CODM;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Extending certain annual disclosures to interim periods; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Clarifying that single reportable segment entities must apply ASC 280 in its entirety.</td></tr></table> ASU 2023-07 is effective for annual periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024, with retrospective application required. The Company adopted ASU 2023-07 for its annual reporting period ended December 31, 2024, and for interim periods beginning January 1, 2025. The adoption resulted in enhanced segment disclosures but did not have a material impact on the Company’s financial position, results of operations, or cash flows. FASB ASU 2023-09 - Income Taxes (Topic 740): Improvements to Income Tax Disclosures In December 2023, the FASB issued ASU 2023-09, which enhances income tax disclosure requirements by: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Standardizing and disaggregating rate reconciliation categories; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Requiring disclosure of income taxes paid by jurisdiction.</td></tr></table> ASU 2023-09 is effective for annual periods beginning after December 15, 2024, and may be applied on a prospective or retrospective basis. The Company adopted ASU 2023-09 effective January 1, 2025. The adoption resulted in enhanced income tax disclosures but did not have a material impact on the Company’s financial position, results of operations, or cash flows. FASB ASU 2025-05 - Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets In July 2025, the FASB issued ASU 2025-05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The ASU provides a practical expedient that permits entities to assume that current economic conditions as of the balance sheet date will remain unchanged over the remaining life of current (short-term) accounts receivable and current contract assets arising from transactions accounted for under ASC 606. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025, and interim periods within those fiscal years, with early adoption permitted in both interim and annual reporting periods in which financial statements have not yet been issued or made available for issuance. The amendments are required to be applied prospectively. The Company early adopted ASU 2025-05 effective January 1, 2025 and elected the practical expedient. The adoption did not have a material impact on the Company’s financial position, results of operations, or cash flows. FASB ASU 2024-04 - Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments In November 2024, the FASB issued ASU 2024-04, which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. The amendments also clarify that the incorporation, elimination, or modification of a volume-weighted average price (VWAP) formula does not automatically result in an extinguishment. ASU 2024-04 is effective for annual periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Adoption may be applied on a prospective or retrospective basis. The Company adopted ASU 2024-04 effective January 1, 2026. The adoption did not have a material impact on the Company’s financial position, results of operations, or cash flows. Recently Issued Accounting Standards Not Yet Adopted FASB ASU 2024-03 / ASU 2025-01 - Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation Disclosures In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which requires public business entities to disclose, in annual and interim reporting periods, disaggregated information about certain income statement expense line items in a tabular format, along with a qualitative reconciliation to the captions on the face of the financial statements. In January 2025, the FASB issued ASU 2025-01 to clarify that the effective date for non-calendar year-end entities requires initial adoption in an annual reporting period, not an interim period. The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and may be applied on either a prospective or retrospective basis. The Company is currently assessing the potential impact of ASU 2024-03 / ASU 2025-01 on its financial statement disclosures. Other Accounting Standards Updates The Company has evaluated all other recently issued accounting standards not yet effective and has determined that the adoption of such standards is not expected to have a material impact on the Company’s financial statements or disclosures. The FASB has also issued various technical corrections and industry-specific updates that are not expected to have a material impact on the Company’s financial position, results of operations, or cash flows.

Note 3 – Property and Equipment Property and equipment consisted of the following: Schedule of property and equipment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Useful Lives (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260630_z2vTQfk5Hgze" style="width: 16%; text-align: right" title="Equipment">227,856</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20251231_zWHiifJzFzB9" style="width: 18%; text-align: right" title="Equipment">227,856</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 18%; text-align: center">5</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20260630_zjkatFzo2zQ7" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation">(141,306</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20251231_zyDYwKvsLpbb" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation">(122,104</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total property and equipment - net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20260630_zRAQehDmnHKl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total property and equipment - net">86,550</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20251231_z4up52Oo6tA" style="border-bottom: Black 2.5pt double; text-align: right" title="Total property and equipment - net">105,752</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Depreciation Expense Schedule of depreciation expense <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 29%"> <tr style="vertical-align: bottom"> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--Depreciation_c20260401__20260630_zWVY7BAoFoxe" style="width: 12%; text-align: right" title="Depreciation expense">9,601</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--Depreciation_c20250401__20250630_z8YLoQRuOGjg" style="width: 12%; text-align: right" title="Depreciation expense">4,650</td><td style="width: 1%; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 29%"> <tr style="vertical-align: bottom"> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Depreciation_c20260101__20260630_zxwNlF0H9IXh" style="width: 12%; text-align: right" title="Depreciation expense">19,202</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--Depreciation_c20250101__20250630_zxbU0u4ZVBTb" style="width: 12%; text-align: right" title="Depreciation expense">9,300</td><td style="width: 1%; text-align: left"> </td></tr> </table>

Property and equipment consisted of the following: Schedule of property and equipment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Useful Lives (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260630_z2vTQfk5Hgze" style="width: 16%; text-align: right" title="Equipment">227,856</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20251231_zWHiifJzFzB9" style="width: 18%; text-align: right" title="Equipment">227,856</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 18%; text-align: center">5</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20260630_zjkatFzo2zQ7" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation">(141,306</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20251231_zyDYwKvsLpbb" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation">(122,104</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total property and equipment - net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20260630_zRAQehDmnHKl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total property and equipment - net">86,550</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20251231_z4up52Oo6tA" style="border-bottom: Black 2.5pt double; text-align: right" title="Total property and equipment - net">105,752</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

227856

P5Y

141306

122104

86550

105752

Schedule of depreciation expense <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 29%"> <tr style="vertical-align: bottom"> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--Depreciation_c20260401__20260630_zWVY7BAoFoxe" style="width: 12%; text-align: right" title="Depreciation expense">9,601</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--Depreciation_c20250401__20250630_z8YLoQRuOGjg" style="width: 12%; text-align: right" title="Depreciation expense">4,650</td><td style="width: 1%; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 29%"> <tr style="vertical-align: bottom"> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Depreciation_c20260101__20260630_zxwNlF0H9IXh" style="width: 12%; text-align: right" title="Depreciation expense">19,202</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--Depreciation_c20250101__20250630_zxbU0u4ZVBTb" style="width: 12%; text-align: right" title="Depreciation expense">9,300</td><td style="width: 1%; text-align: left"> </td></tr> </table>

9601

4650

19202

9300

Note 4 – Convertible Advance Payable The Company’s advances payable are as follows: Schedule of convertible advance payable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Terms</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Convertible Advance Payable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance date of advances</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">Prior to 2018</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Maturity date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">Due on Demand</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 57%; text-align: left">Interest rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_ecustom--DebtInstrumentInterestRateStatedPercentage1_iI_pid_dp_uRatio_c20260630_zEd4tWm220ld" style="width: 20%; text-align: center" title="Interest rate">0%</td><td style="width: 1%; text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Collateral</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">Unsecured</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: top">Conversion feature</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">45% discount to market price</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>December 31, 2024</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ConvertibleAdvancePayableBeginning_c20250101__20251231_zOIRLg8lMSkj" style="text-align: right" title="Beginning Balance">563,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">No activity in 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ConvertibleAdvancePayableBeginning_c20260101__20260630_z0QdCRHRvL2k" style="text-align: right" title="Beginning Balance">563,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">No activity in 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ConvertibleAdvancePayableEnding_c20260101__20260630_zMObut542Eqe" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">563,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company has a $310,000 advance payable to a former Chief Financial Officer of the Company. The advance was originally issued with no formal terms. Pursuant to a prior settlement, the creditor holds the option of repayment in either cash or shares of the Company’s common stock, at a <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_pid_dp_uRatio_c20260101__20260630__us-gaap--StatementClassOfStockAxis__custom--CommonStocksMember_zHAcv8I4ID49" title="Discount to current market price of the common stock">45% discount to the current market price of the common stock. The Company has accounted for the advance payable under FASB ASC 480-10-25-14, given the obligation to issue a variable number of shares based solely or predominately on a fixed monetary amount, and recorded the liability at its fixed monetary amount of $563,000 representing the holder’s discount to market on its common shares expected upon settlement. The Company’s advances payable are as follows: Schedule of convertible advance payable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Terms</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Convertible Advance Payable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance date of advances</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">Prior to 2018</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Maturity date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">Due on Demand</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 57%; text-align: left">Interest rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_ecustom--DebtInstrumentInterestRateStatedPercentage1_iI_pid_dp_uRatio_c20260630_zEd4tWm220ld" style="width: 20%; text-align: center" title="Interest rate">0%</td><td style="width: 1%; text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Collateral</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">Unsecured</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: top">Conversion feature</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">45% discount to market price</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>December 31, 2024</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ConvertibleAdvancePayableBeginning_c20250101__20251231_zOIRLg8lMSkj" style="text-align: right" title="Beginning Balance">563,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">No activity in 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ConvertibleAdvancePayableBeginning_c20260101__20260630_z0QdCRHRvL2k" style="text-align: right" title="Beginning Balance">563,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">No activity in 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ConvertibleAdvancePayableEnding_c20260101__20260630_zMObut542Eqe" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">563,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Prior to 2018 Due on Demand 0 Unsecured

45% discount to market price

563000 563000 563000 310000

0.45

563000

Note 5 – Debt Notes Payable - Related Parties The Company has entered into several notes payable with related parties, each of whom is a member of the Board of Directors. A summary of notes payable - related parties as of June 30, 2026 and December 31, 2025 is as follows: Schedule of notes payable to related party <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 0.5pt solid; font-weight: bold; text-align: center; width: 18%">Terms</td> <td style="width: 2%"> </td> <td style="border-bottom: Black 0.5pt solid; font-weight: bold; text-align: center; width: 16%">Note Payable #1 Related Party</td> <td style="font-weight: bold; text-align: center; width: 2%"> </td> <td style="border-bottom: Black 0.5pt solid; font-weight: bold; text-align: center; width: 16%">Note Payable #2 Related Party</td> <td style="font-weight: bold; text-align: center; width: 2%"> </td> <td style="border-bottom: Black 0.5pt solid; font-weight: bold; text-align: center; width: 16%">Note Payable #3 Related Party</td> <td style="width: 2%"> </td> <td style="border-bottom: Black 0.5pt solid; font-weight: bold; text-align: center; width: 16%">Note Payable #4 Related Party</td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td> <td> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Issuance dates of notes</td> <td> </td> <td style="text-align: center"><span id="xdx_905_eus-gaap--DebtInstrumentMaturityDateDescription_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zCQPCyASslIl" title="Issuance dates of notes">August 2022</td> <td style="text-align: left"> </td> <td style="text-align: center"><span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateDescription_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zg5sVvWAcjt2" title="Issuance dates of notes">April 2023</td> <td style="text-align: center"> </td> <td style="text-align: center"><span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDateDescription_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_zerkKkEjtgp5" title="Issuance dates of notes">August 2024</td> <td> </td> <td style="text-align: center"><span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateDescription_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_zew6l9gKMMoc" title="Issuance dates of notes">February 2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-indent: -0.125in">Maturity date</td> <td> </td> <td style="text-align: center"><span id="xdx_90B_ecustom--DebtInstrumentMaturityDateDescription1_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zQs2ebM8FTn" title="Maturity date">December 2026</td> <td style="text-align: left"> </td> <td style="text-align: center"><span id="xdx_901_ecustom--DebtInstrumentMaturityDateDescription1_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zkOPoMZdHC3c" title="Maturity date">March 2025</td> <td style="text-align: center"> </td> <td style="text-align: center"><span id="xdx_90E_ecustom--DebtInstrumentMaturityDateDescription1_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_z01u2MVgGOnj" title="Maturity date">December 2024</td> <td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--DebtInstrumentMaturityDateDescription1_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_z2y30noecLG1" title="Maturity date">March 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Interest rate</td> <td> </td> <td style="text-align: center"><span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uRatio_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zJnCPYErvPXi" title="Interest rate">10%</td> <td style="text-align: left"> </td> <td style="text-align: center"><span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uRatio_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zDe16NVxQQUh" title="Interest rate">8%</td> <td style="text-align: center"> </td> <td style="text-align: center"><span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uRatio_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_zr77LZUVpOCj" title="Interest rate">0%</td> <td> </td> <td style="text-align: center"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uRatio_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_zJjNzytGE5Bh" title="Interest rate">0%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-indent: -0.125in">Imputed interest rate</td> <td> </td> <td style="text-align: center">N/A</td> <td style="text-align: left"> </td> <td style="text-align: center">N/A</td> <td style="text-align: center"> </td> <td style="text-align: center"><span id="xdx_900_ecustom--DebtInstrumentImputedInterestExpenseRatePercentage_iI_pid_dp_uRatio_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_zqPqnpHHuOU6" title="Imputed interest rate">8%</td> <td> </td> <td style="text-align: center"><span id="xdx_901_ecustom--DebtInstrumentImputedInterestExpenseRatePercentage_iI_pid_dp_uRatio_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_z63ijogX14Kg" title="Imputed interest rate">8%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Default interest rate</td> <td> </td> <td style="text-align: center"><span id="xdx_905_ecustom--DebtInstrumentDefaultInterestRatePercentage_iI_pid_dp_uRatio_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zXLW2icAufj7" title="Default interest rate">20%</td> <td style="text-align: left"> </td> <td style="text-align: center"><span id="xdx_907_ecustom--DebtInstrumentDefaultInterestRatePercentage_iI_pid_dp_uRatio_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zJGmhT6ETGZk" title="Default interest rate">20%</td> <td style="text-align: center"> </td> <td style="text-align: center"><span id="xdx_90E_ecustom--DebtInstrumentDefaultInterestRatePercentage_iI_pid_dp_uRatio_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_zuH71XRxF8I1" title="Default interest rate">20%</td> <td> </td> <td style="text-align: center">None</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Collateral</td> <td> </td> <td style="text-align: center"><span id="xdx_90F_eus-gaap--DebtInstrumentCollateral_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zWzZzMAVMDQk" title="Collateral">PET-CT Imaging Device</td> <td style="text-align: left"> </td> <td style="text-align: center"><span id="xdx_901_eus-gaap--DebtInstrumentCollateral_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zbMxhNGS5TOj" title="Collateral">PET-CT Imaging Device</td> <td style="text-align: center"> </td> <td style="text-align: center"><span id="xdx_907_eus-gaap--DebtInstrumentCollateral_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_zn2GyWmP2Gs8" title="Collateral">PET-CT Imaging Device</td> <td> </td> <td style="text-align: center; vertical-align: top"><span id="xdx_90C_eus-gaap--DebtInstrumentCollateral_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_z19DvJI1ej89" title="Collateral">Unsecured</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; padding-left: 0.125in; text-indent: -0.125in">December 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ConvertibleNotesPayableCurrent_iS_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zYw8mLiyfz5c" style="width: 12%; text-align: right" title="Beginning balance">1,200,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ConvertibleNotesPayableCurrent_iS_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zqgrHyHFf27c" style="width: 12%; text-align: right" title="Beginning balance">150,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ConvertibleNotesPayableCurrent_iS_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_zm320WxCRx1f" style="width: 12%; text-align: right" title="Beginning balance">100,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ConvertibleNotesPayableCurrent_iS_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_zQdECtAkUKu1" style="width: 12%; text-align: right" title="Beginning balance">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ConvertibleNotesPayableCurrent_iS_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__us-gaap--NotesPayableCurrent_ztwBZc8lYYZe" style="width: 12%; text-align: right" title="Beginning balance">1,450,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Proceeds from issuance of note</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ProceedsFromNotesPayable_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zVVXh2VMjlJg" style="text-align: right" title="Proceeds from issuance of note">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ProceedsFromNotesPayable_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zclGdRDhZdf" style="text-align: right" title="Proceeds from issuance of note">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ProceedsFromNotesPayable_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_zBx13JbQRC4k" style="text-align: right" title="Proceeds from issuance of note">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ProceedsFromNotesPayable_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_zIhqDLJcVzka" style="text-align: right" title="Proceeds from issuance of note">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ProceedsFromNotesPayable_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__us-gaap--NotesPayableCurrent_zencCo5onXsb" style="text-align: right" title="Proceeds from issuance of note">100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">Repayments</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zS6EjvMJSfL7" style="border-bottom: Black 1pt solid; text-align: right" title="Repayments">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zT69hk9SRbzc" style="border-bottom: Black 1pt solid; text-align: right" title="Repayments">(150,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_zSfD7Dqmlkm1" style="border-bottom: Black 1pt solid; text-align: right" title="Repayments">(100,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_zXXncjxFwxHc" style="border-bottom: Black 1pt solid; text-align: right" title="Repayments">(100,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__us-gaap--NotesPayableCurrent_zaBjXgeFPsZ9" style="border-bottom: Black 1pt solid; text-align: right" title="Repayments">(350,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-indent: -0.125in">December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ConvertibleNotesPayableCurrent_iS_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zAAdvfLKSQgk" style="text-align: right" title="Beginning balance">1,200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ConvertibleNotesPayableCurrent_iS_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zC78hPzX5AI8" style="text-align: right" title="Beginning balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ConvertibleNotesPayableCurrent_iS_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_z5WOpUuNndM4" style="text-align: right" title="Beginning balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ConvertibleNotesPayableCurrent_iS_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_zz5XCVfFzTfc" style="text-align: right" title="Beginning balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConvertibleNotesPayableCurrent_iS_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__us-gaap--NotesPayableCurrent_zfbSyoQHfwRe" style="text-align: right" title="Beginning balance">1,200,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">Repayments</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zBj4lqabILc1" style="border-bottom: Black 1pt solid; text-align: right" title="Repayments">(325,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zXChLceby6cf" style="border-bottom: Black 1pt solid; text-align: right" title="Repayments">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_zRjF4tU09goh" style="border-bottom: Black 1pt solid; text-align: right" title="Repayments">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_ziRYIeyLQM02" style="border-bottom: Black 1pt solid; text-align: right" title="Repayments">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__us-gaap--NotesPayableCurrent_zltZcGOKxgu4" style="border-bottom: Black 1pt solid; text-align: right" title="Repayments">(325,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in">June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ConvertibleNotesPayableCurrent_iE_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zLzJDwukZfii" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">875,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ConvertibleNotesPayableCurrent_iE_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zYN3AO4pRX6a" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ConvertibleNotesPayableCurrent_iE_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_z1P84mWz1oih" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ConvertibleNotesPayableCurrent_iE_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_zlds2YSXrvMe" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ConvertibleNotesPayableCurrent_iE_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__us-gaap--NotesPayableCurrent_z2SiEkjmDhOf" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">875,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Note #1 In March 2025, Note #1 was extended to December 31, 2025. On February 16, 2026, Note #1 was further extended to June 30, 2026. On June 30, 2026, Note #1 was further extended to December 31, 2026. The Company evaluated each extension under FASB ASC 470-50-40 and concluded that the extensions did not constitute a substantive modification. Accordingly, no debt extinguishment occurred and no gain or loss was recognized. Note #1 is collateralized by the Company’s sole imaging device, which is carried in inventory. The lender has authorized the sale of the collateral, and the loan agreement requires sale proceeds to be applied toward the outstanding loan balance. During the six months ended June 30, 2026, the Company repaid $325,000. Note #2 In April 2023, the Company executed a one-year note with a shareholder and director in the principal amount of $<span id="xdx_900_ecustom--NotesPayableRelatedPartiesCurrent_iI_c20230430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember_zgM1DPT02YO5" title="Notes Payable Related Parties Current">500,000. The note bears interest at <span id="xdx_909_ecustom--DebtInstrumentsInterestRateStatedPercentage_iI_pid_dp_uRatio_c20230430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zIa0nDnr0hU4" title="Interest Rate">8.0% per annum, with a default rate of <span id="xdx_905_ecustom--DebtInstrumentsDefaultInterestRatePercentage_iI_pid_dp_uRatio_c20230430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zSNY6i21UYh5" title="Default Interest Rate">20.0%, and is secured by the net proceeds from the Company’s PET imaging devices and service contracts. Original principal was payable 50% on December 31, 2023 and 50% plus accrued interest on March 31, 2024. The note was extended and repaid in full as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">In March 2024, the remaining balance of $<span id="xdx_904_ecustom--NotesPayableRelatedPartiesCurrent_iI_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember_z1Au0dPgUrYi" title="Notes Payable Related Parties Current">250,000 was extended to September 2024. During 2024, $100,000 of principal was repaid.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">In September 2024, the remaining balance of $<span id="xdx_90B_ecustom--NotesPayableRelatedPartiesCurrent_iI_c20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember_zAWh2i6r1KF7" title="Notes Payable Related Parties Current">150,000 was extended to March 2025.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">During 2025, the remaining $150,000 of principal was repaid in full, and $41,414 of accrued interest was forgiven by the lender.</td></tr></table> Because the lender is a significant stockholder and director, the Company accounted for the interest forgiveness as a capital contribution, recording $41,414 as an increase to additional paid-in capital rather than as a gain on extinguishment. This treatment is consistent with FASB ASC 470-50-40-2, which addresses extinguishment transactions between related parties, and with FASB ASC 850-10-50-5, which requires related-party transactions to be presented in accordance with their substance rather than as arm’s length transactions. The Company evaluated the 2024 and 2025 extensions under FASB ASC 470-50-40 and concluded that the extensions did not add or eliminate a substantive conversion feature, did not result in cash flows that differed by 10% or more from those under the original instrument, and did not result in significant changes to interest rate, collateral, or repayment terms beyond the extension of maturity. Accordingly, no debt extinguishment occurred and no gain or loss was recognized. In connection with the original issuance of the note in 2023, the Company issued 100,000 warrants to the lender with an exercise price of $0.10 per share. The warrants vested immediately and had an original expiration date of December 31, 2025. The fair value of the warrants of $126,699 was recorded as a debt discount and amortized over the original term of the note. On December 31, 2025, the expiration date of the warrants was extended to December 31, 2026, with no financial statement impact (see Note 9). Note #3 In August 2024, the Company executed a four-month, non-interest-bearing note with a shareholder and director in the principal amount of $<span id="xdx_90E_ecustom--NotesPayableRelatedPartiesCurrent_iI_c20240831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember_zqqqICnflaUc" title="Notes Payable Related Parties Current">100,000, with a default interest rate of <span id="xdx_90B_ecustom--DebtInstrumentsDefaultInterestRatePercentage_iI_pid_dp_uRatio_c20240831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_zrBCbQRNHxQc" title="Default Interest Rate">20%. The note was secured by the net proceeds from the Company’s PET imaging devices and service contracts. Because the note was issued by a related party at a below-market interest rate, the Company recorded imputed interest at <span id="xdx_900_ecustom--DebtInstrumentsImputedInterestExpenseRatePercentage_iI_pid_dp_uRatio_c20240831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_z1BwMMJrFdqi" title="Imputed interest rate">8%, resulting in interest expense of $<span id="xdx_904_ecustom--DebtInstrumentImputedInterestExpenseRateAmount_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember_zXLkCdvoJjh7" title="Debt Instrument Imputed Interest Expense Rate Amount">1,600 for the year ended December 31, 2024, with a corresponding credit to additional paid-in capital. The note was repaid in full in March 2025. Note #4 In February 2025, the Company executed a one-month, non-interest-bearing, unsecured note with a shareholder and director in the principal amount of $<span id="xdx_908_ecustom--NotesPayableRelatedPartiesCurrent_iI_c20250228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember_zo9I4bejzfk2" title="Notes Payable Related Parties Current">100,000. The Company recorded imputed interest at <span id="xdx_903_ecustom--DebtInstrumentsImputedInterestExpenseRatePercentage_iI_pid_dp_uRatio_c20250228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_zyfRzcKZHXf5" title="Imputed interest rate">8%, resulting in interest expense of $<span id="xdx_90F_ecustom--DebtInstrumentImputedInterestExpenseRateAmount_iI_c20250228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember_zOfj6PPcaAVb" title="Debt Instrument Imputed Interest Expense Rate Amount">1,336 for the year ended December 31, 2025, with a corresponding credit to additional paid-in capital. The note was repaid in full during 2025.

The Company has entered into several notes payable with related parties, each of whom is a member of the Board of Directors. A summary of notes payable - related parties as of June 30, 2026 and December 31, 2025 is as follows: Schedule of notes payable to related party <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 0.5pt solid; font-weight: bold; text-align: center; width: 18%">Terms</td> <td style="width: 2%"> </td> <td style="border-bottom: Black 0.5pt solid; font-weight: bold; text-align: center; width: 16%">Note Payable #1 Related Party</td> <td style="font-weight: bold; text-align: center; width: 2%"> </td> <td style="border-bottom: Black 0.5pt solid; font-weight: bold; text-align: center; width: 16%">Note Payable #2 Related Party</td> <td style="font-weight: bold; text-align: center; width: 2%"> </td> <td style="border-bottom: Black 0.5pt solid; font-weight: bold; text-align: center; width: 16%">Note Payable #3 Related Party</td> <td style="width: 2%"> </td> <td style="border-bottom: Black 0.5pt solid; font-weight: bold; text-align: center; width: 16%">Note Payable #4 Related Party</td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td> <td> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Issuance dates of notes</td> <td> </td> <td style="text-align: center"><span id="xdx_905_eus-gaap--DebtInstrumentMaturityDateDescription_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zCQPCyASslIl" title="Issuance dates of notes">August 2022</td> <td style="text-align: left"> </td> <td style="text-align: center"><span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateDescription_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zg5sVvWAcjt2" title="Issuance dates of notes">April 2023</td> <td style="text-align: center"> </td> <td style="text-align: center"><span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDateDescription_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_zerkKkEjtgp5" title="Issuance dates of notes">August 2024</td> <td> </td> <td style="text-align: center"><span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateDescription_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_zew6l9gKMMoc" title="Issuance dates of notes">February 2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-indent: -0.125in">Maturity date</td> <td> </td> <td style="text-align: center"><span id="xdx_90B_ecustom--DebtInstrumentMaturityDateDescription1_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zQs2ebM8FTn" title="Maturity date">December 2026</td> <td style="text-align: left"> </td> <td style="text-align: center"><span id="xdx_901_ecustom--DebtInstrumentMaturityDateDescription1_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zkOPoMZdHC3c" title="Maturity date">March 2025</td> <td style="text-align: center"> </td> <td style="text-align: center"><span id="xdx_90E_ecustom--DebtInstrumentMaturityDateDescription1_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_z01u2MVgGOnj" title="Maturity date">December 2024</td> <td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--DebtInstrumentMaturityDateDescription1_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_z2y30noecLG1" title="Maturity date">March 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Interest rate</td> <td> </td> <td style="text-align: center"><span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uRatio_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zJnCPYErvPXi" title="Interest rate">10%</td> <td style="text-align: left"> </td> <td style="text-align: center"><span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uRatio_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zDe16NVxQQUh" title="Interest rate">8%</td> <td style="text-align: center"> </td> <td style="text-align: center"><span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uRatio_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_zr77LZUVpOCj" title="Interest rate">0%</td> <td> </td> <td style="text-align: center"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uRatio_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_zJjNzytGE5Bh" title="Interest rate">0%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-indent: -0.125in">Imputed interest rate</td> <td> </td> <td style="text-align: center">N/A</td> <td style="text-align: left"> </td> <td style="text-align: center">N/A</td> <td style="text-align: center"> </td> <td style="text-align: center"><span id="xdx_900_ecustom--DebtInstrumentImputedInterestExpenseRatePercentage_iI_pid_dp_uRatio_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_zqPqnpHHuOU6" title="Imputed interest rate">8%</td> <td> </td> <td style="text-align: center"><span id="xdx_901_ecustom--DebtInstrumentImputedInterestExpenseRatePercentage_iI_pid_dp_uRatio_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_z63ijogX14Kg" title="Imputed interest rate">8%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Default interest rate</td> <td> </td> <td style="text-align: center"><span id="xdx_905_ecustom--DebtInstrumentDefaultInterestRatePercentage_iI_pid_dp_uRatio_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zXLW2icAufj7" title="Default interest rate">20%</td> <td style="text-align: left"> </td> <td style="text-align: center"><span id="xdx_907_ecustom--DebtInstrumentDefaultInterestRatePercentage_iI_pid_dp_uRatio_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zJGmhT6ETGZk" title="Default interest rate">20%</td> <td style="text-align: center"> </td> <td style="text-align: center"><span id="xdx_90E_ecustom--DebtInstrumentDefaultInterestRatePercentage_iI_pid_dp_uRatio_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_zuH71XRxF8I1" title="Default interest rate">20%</td> <td> </td> <td style="text-align: center">None</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Collateral</td> <td> </td> <td style="text-align: center"><span id="xdx_90F_eus-gaap--DebtInstrumentCollateral_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zWzZzMAVMDQk" title="Collateral">PET-CT Imaging Device</td> <td style="text-align: left"> </td> <td style="text-align: center"><span id="xdx_901_eus-gaap--DebtInstrumentCollateral_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zbMxhNGS5TOj" title="Collateral">PET-CT Imaging Device</td> <td style="text-align: center"> </td> <td style="text-align: center"><span id="xdx_907_eus-gaap--DebtInstrumentCollateral_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_zn2GyWmP2Gs8" title="Collateral">PET-CT Imaging Device</td> <td> </td> <td style="text-align: center; vertical-align: top"><span id="xdx_90C_eus-gaap--DebtInstrumentCollateral_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_z19DvJI1ej89" title="Collateral">Unsecured</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; padding-left: 0.125in; text-indent: -0.125in">December 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ConvertibleNotesPayableCurrent_iS_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zYw8mLiyfz5c" style="width: 12%; text-align: right" title="Beginning balance">1,200,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ConvertibleNotesPayableCurrent_iS_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zqgrHyHFf27c" style="width: 12%; text-align: right" title="Beginning balance">150,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ConvertibleNotesPayableCurrent_iS_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_zm320WxCRx1f" style="width: 12%; text-align: right" title="Beginning balance">100,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ConvertibleNotesPayableCurrent_iS_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_zQdECtAkUKu1" style="width: 12%; text-align: right" title="Beginning balance">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ConvertibleNotesPayableCurrent_iS_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__us-gaap--NotesPayableCurrent_ztwBZc8lYYZe" style="width: 12%; text-align: right" title="Beginning balance">1,450,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Proceeds from issuance of note</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ProceedsFromNotesPayable_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zVVXh2VMjlJg" style="text-align: right" title="Proceeds from issuance of note">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ProceedsFromNotesPayable_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zclGdRDhZdf" style="text-align: right" title="Proceeds from issuance of note">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ProceedsFromNotesPayable_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_zBx13JbQRC4k" style="text-align: right" title="Proceeds from issuance of note">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ProceedsFromNotesPayable_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_zIhqDLJcVzka" style="text-align: right" title="Proceeds from issuance of note">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ProceedsFromNotesPayable_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__us-gaap--NotesPayableCurrent_zencCo5onXsb" style="text-align: right" title="Proceeds from issuance of note">100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">Repayments</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zS6EjvMJSfL7" style="border-bottom: Black 1pt solid; text-align: right" title="Repayments">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zT69hk9SRbzc" style="border-bottom: Black 1pt solid; text-align: right" title="Repayments">(150,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_zSfD7Dqmlkm1" style="border-bottom: Black 1pt solid; text-align: right" title="Repayments">(100,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_zXXncjxFwxHc" style="border-bottom: Black 1pt solid; text-align: right" title="Repayments">(100,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__us-gaap--NotesPayableCurrent_zaBjXgeFPsZ9" style="border-bottom: Black 1pt solid; text-align: right" title="Repayments">(350,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-indent: -0.125in">December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ConvertibleNotesPayableCurrent_iS_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zAAdvfLKSQgk" style="text-align: right" title="Beginning balance">1,200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ConvertibleNotesPayableCurrent_iS_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zC78hPzX5AI8" style="text-align: right" title="Beginning balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ConvertibleNotesPayableCurrent_iS_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_z5WOpUuNndM4" style="text-align: right" title="Beginning balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ConvertibleNotesPayableCurrent_iS_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_zz5XCVfFzTfc" style="text-align: right" title="Beginning balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConvertibleNotesPayableCurrent_iS_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__us-gaap--NotesPayableCurrent_zfbSyoQHfwRe" style="text-align: right" title="Beginning balance">1,200,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">Repayments</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zBj4lqabILc1" style="border-bottom: Black 1pt solid; text-align: right" title="Repayments">(325,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zXChLceby6cf" style="border-bottom: Black 1pt solid; text-align: right" title="Repayments">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_zRjF4tU09goh" style="border-bottom: Black 1pt solid; text-align: right" title="Repayments">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_ziRYIeyLQM02" style="border-bottom: Black 1pt solid; text-align: right" title="Repayments">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__us-gaap--NotesPayableCurrent_zltZcGOKxgu4" style="border-bottom: Black 1pt solid; text-align: right" title="Repayments">(325,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in">June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ConvertibleNotesPayableCurrent_iE_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable1RelatedPartyMember_zLzJDwukZfii" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">875,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ConvertibleNotesPayableCurrent_iE_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable2RelatedPartyMember_zYN3AO4pRX6a" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ConvertibleNotesPayableCurrent_iE_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable3RelatedPartyMember_z1P84mWz1oih" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ConvertibleNotesPayableCurrent_iE_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__custom--NotePayable4RelatedPartyMember_zlds2YSXrvMe" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ConvertibleNotesPayableCurrent_iE_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndDirectorMember__us-gaap--FinancialInstrumentAxis__us-gaap--NotesPayableCurrent_z2SiEkjmDhOf" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">875,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

August 2022

April 2023

August 2024

February 2025

December 2026 March 2025 December 2024 March 2025

0.10

0.08

0.08 0.08 0.20 0.20 0.20

PET-CT Imaging Device

Unsecured

1200000

150000

100000

1450000

100000

150000

100000

350000

1200000

325000

875000

325000

500000 0.080 0.200 0.50 0.50 250000

100000

150000

41414

100000

0.10

126699

100000 0.20 0.08 1600 100000 0.08 1336

Note 6 – Commitments and Contingencies Operating Lease The Company accounts for leases in accordance with FASB ASC 842: Leases, which requires lessees to apply the right-of-use (ROU) model by recognizing a right-of-use asset and a lease liability for all leases with terms exceeding 12 months. Lease classification determines the pattern of expense recognition in the Statements of Operations: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Operating leases: Recognized on a straight-line basis as lease expense over the lease term.</td></tr></table> Lease Recognition and Measurement The Company evaluates whether an arrangement contains a lease at inception and recognizes the lease in the financial statements upon lease commencement (the date the underlying asset is available for use). ROU assets represent the Company’s right to use an asset over the lease term, while lease liabilities reflect the present value of future lease payments. At lease commencement: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">ROU assets and lease liabilities are initially measured at the present value of lease payments.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">The Company primarily uses its incremental borrowing rate (IBR) to determine the present value of lease payments, except when an implicit rate is readily determinable.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">The IBR is based on market data, adjusted for credit risk and lease term.</td></tr></table> Practical Expedients and Lease Components The Company applies certain practical expedients to simplify lease accounting: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Lease and non-lease components are combined for classification and measurement, except for direct sales-type leases and production equipment embedded in supply agreements.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Short-term leases (12 months or less, without purchase or renewal options) are not recorded on the balance sheet.</td></tr></table> Lease Term and Expense Recognition <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Lease liabilities include options to extend or terminate when reasonably certain of exercise.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Operating lease expense is recognized on a straight-line basis over the lease term and reported under general and administrative expenses.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Variable lease payments based on an index/rate are initially measured using the rate at lease commencement, with differences expensed as incurred.</td></tr></table> Company Lease Commitments As of June 30, 2026 and December 31, 2025, the Company had no finance leases under FASB ASC 842. Right-of-Use Operating Lease On July 8, 2025, the Company executed a five-year lease for its office space, covering the period from July 8, 2025 to July 8, 2030. See below regarding original lease and related termination of that lease. <div id="xdx_C0F_gIFLOLD-BGF1_zcxA18cQWH79"> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Lease term: 60 months (five years)</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Monthly lease payments: </td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">○</td><td style="text-align: justify">Months 1-12: $3,626 per month</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">○</td><td style="text-align: justify">Months 13-24: $3,777 per month</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">○</td><td style="text-align: justify">Months 25-60: $4,200 per month</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Total lease payments: $240,036 (excluding variable monthly operating expenses)</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Occupancy date: August 1, 2025</td></tr></table></div> <div id="xdx_C0D_gIFLOLD-BGF2_zMIfrTGt1lvi"> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Renewal option: The lease has no renewal options.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Lease classification: The lease is evaluated under FASB ASC 842, Leases, and recorded as a right-of-use (ROU) asset and lease liability based on the present value of lease payments ($196,049) at lease commencement.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Lease incentives/allowances – none</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Guarantee – The lease is guaranteed by the Company’s Chief Executive Officer. The guarantee is unconditional and continuing, and covers the full performance of the lease obligations, including payment of rent and fulfillment of all tenant responsibilities.</td></tr></table></div> The Company recognizes lease expense on a straight-line basis over the lease term. Right-of-Use Operating Lease – Lease Termination On June 26, 2025, the Company entered into an agreement to terminate its existing operating lease (originally executed March 17, 2022), which was originally scheduled to expire on May 31, 2027. The last payment was made July 1, 2025. Pursuant to the agreement, the termination is effective as of August 31, 2025. As part of the termination agreement, the Company paid a lump-sum settlement of $20,000 to the lessor. This payment has been recorded as a lease termination expense in the Statements of Operations in 2025. Upon termination, the Company: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify; padding-right: 5.7pt">Derecognized the right-of-use (ROU) asset and the corresponding lease liability related to the lease;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify; padding-right: 5.7pt">Recognized any difference between the asset and liability as a gain or loss on lease termination;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify; padding-right: 5.7pt">Included the $20,000 termination fee in the total expense recognized upon derecognition.</td></tr></table> Loss on lease termination of $15,018 was calculated as follows: Schedule of loss on lease termination <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 45%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255); visibility: hidden"> <td style="display: none; text-align: left; visibility: hidden"> </td><td style="display: none; visibility: hidden"> </td> <td style="display: none; text-align: left; visibility: hidden"> </td><td id="xdx_494_20260630_zLxY0BIxEJQa" style="display: none; text-align: right; visibility: hidden"> </td><td style="display: none; text-align: left; visibility: hidden"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: left">Right-of-Use Asset</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAsset_iI_dxL_c20260630_zxAqr9vbcwWa" style="width: 10%; text-align: right" title="Right-of-Use Asset::XDX::160107">28,228</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--CashPaidToTerminateLease_iI_uUSD_z3hrRnEuU57e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cash paid to terminate lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--OperatingLeaseLiabilities_iI_uUSD_zXD9TYejRsDl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(33,210</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_ecustom--LossOnTerminationOfLease_iI_uUSD_zyhXk2F6dCrj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss on lease termination</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,018</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> On March 17, 2022, the Company executed a five-year lease extension for its office space, covering the period from June 1, 2022, through May 31, 2027. <div id="xdx_C05_gIFLOLD-RYJFYT1_zjrd63SoLjo"> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Lease term: 60 months (five years)</td></tr></table></div> <div id="xdx_C0E_gIFLOLD-RYJFYT2_z1RodNqETy1f"> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Monthly lease payments: </td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">○</td><td style="text-align: justify">Years 1-3: $1,600 per month</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">○</td><td style="text-align: justify">Years 4-5: $1,700 per month</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Total lease payments: $57,600 for the first three years and $40,800 for the last two years</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Renewal option: The Company has the option to extend the lease for an additional five years through May 31, 2032.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Lease classification: The lease is evaluated under FASB ASC 842, Leases, and recorded as a right-of-use (ROU) asset and lease liability based on the present value of lease payments at lease commencement.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Renewal option assessment: At lease inception, based on historical operations, the Company does not expect to exercise the renewal option and has excluded it from lease liability calculations.</td></tr></table></div> The Company recognizes lease expense on a straight-line basis over the lease term. The tables below present information regarding the Company’s operating lease asset and liability at June 30, 2026 and December 31, 2025, respectively: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>Schedule of operating lease asset and liability</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left; padding-bottom: 2.5pt">Operating lease - right-of-use asset - non-current</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20260630_zLYgYJ04S6Ji" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right">160,107</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20251231_zHvgNZY5CGl3" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right">179,711</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseLiability_iI_c20260630_zqJ6AkI6Rc6h" style="border-bottom: Black 2.5pt double; text-align: right">169,672</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingLeaseLiability_iI_c20251231_zSbtZ4c3swo" style="border-bottom: Black 2.5pt double; text-align: right">184,298</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average remaining lease term (years)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260630_zYzvTMB1mN6" style="border-bottom: Black 2.5pt double; text-align: right">4.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zPh1fU0NqKy6" style="border-bottom: Black 2.5pt double; text-align: right">4.58</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average discount rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uRatio_c20260630_zFT09vfGqRB7" style="border-bottom: Black 2.5pt double; text-align: right">8</td><td style="padding-bottom: 2pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uRatio_c20251231_zmopXqjqv8c3" style="border-bottom: Black 2.5pt double; text-align: right">8</td><td style="padding-bottom: 2pt; text-align: left">%</td></tr> </table> The components of lease expense were as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in">Schedule of operating lease expense</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating lease costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Amortization of right-of-use operating lease asset</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_c20260101__20260630_z1SpGIcXfSO7" style="width: 18%; text-align: right" title="Amortization of right-of-use operating lease asset">19,604</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_c20250101__20250630_zsXsV6MT9MU3" style="width: 18%; text-align: right" title="Amortization of right-of-use operating lease asset">8,065</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">Lease liability expense in connection with obligation repayment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--RepaymentsOfDebtAndCapitalLeaseObligations_c20260101__20260630_zPxxx2B1VBwc" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liability expense in connection with obligation repayment">7,130</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--RepaymentsOfDebtAndCapitalLeaseObligations_c20250101__20250630_zN82hhpiJgwh" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liability expense in connection with obligation repayment">1,635</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in">Total operating lease costs</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--TotalOperatingLeaseCosts_c20260101__20260630_zpinClcHssR4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total operating lease costs">26,734</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--TotalOperatingLeaseCosts_c20250101__20250630_z2DZSiSrZIo" style="border-bottom: Black 2.5pt double; text-align: right" title="Total operating lease costs">9,700</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Supplemental cash flow information related to operating leases was as follows:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in">Operating cash outflows from operating lease (obligation payment)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeasePaymentsUse_c20260101__20260630_zztNZ15tqLs8" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating cash outflows from operating lease (obligation payment)">21,756</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeasePaymentsUse_c20250101__20250630_zYFB2wsJoXik" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating cash outflows from operating lease (obligation payment)">9,700</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in">Right-of-use asset obtained in exchange for new operating lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_dxL_c20260101__20260630_zCknTOsoE4dc" style="border-bottom: Black 2.5pt double; text-align: right" title="Right-of-use asset obtained in exchange for new operating lease liability::XDX::0">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_dxL_c20250101__20250630_znD6z3Z7sBAk" style="border-bottom: Black 2.5pt double; text-align: right" title="Right-of-use asset obtained in exchange for new operating lease liability::XDX::0">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Future minimum lease payments required under leases that have initial or remaining non-cancelable lease terms in excess of one year at December 31,: Schedule of future minimum lease payments <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2026 (6 months)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20260630_zPj2UMuU73qj" style="width: 12%; text-align: right" title="2026 (6 months)">22,511</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20260630_zRhIiEK6NhKg" style="text-align: right" title="2027">47,439</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20260630_zxFKqYvs2A23" style="text-align: right" title="2028">50,400</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2029</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20260630_zdNYSv7fUUP1" style="text-align: right" title="2029">50,400</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--OperatingLeasesFutureMinimumPaymentDueThereafter_iI_uUSD_c20260630_zRJ1Pi2hsja9" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter">29,400</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total undiscounted cash flows</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20260630_zbOO8msVtFh3" style="text-align: right" title="Total undiscounted cash flows">200,150</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: amount representing interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_c20260630_zp8MpJ5Mnv95" style="border-bottom: Black 1pt solid; text-align: right" title="Less: amount representing interest">30,478</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Present value of operating lease liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--OperatingLeasesLiability_iI_c20260630_z8E2TetPkofc" style="text-align: right" title="Present value of operating lease liability">169,672</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: current portion of operating lease liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20260630_zbtPr8U1fpHd" style="border-bottom: Black 1pt solid; text-align: right" title="Less: current portion of operating lease liability">32,778</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Long-term operating lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20260630_zkqksRzITfO2" style="border-bottom: Black 2.5pt double; text-align: right" title="Long-term operating lease liability">136,894</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Contingencies – Strategic Cooperation Agreement On January 15, 2022, the Company entered into a strategic cooperation agreement with a supplier for the development, manufacture, and distribution of PET/CT imaging systems. The agreement establishes transfer pricing terms for PET/CT systems that become effective only upon receipt of U.S. Food and Drug Administration (FDA) clearance for the Company’s next-generation PET/CT 4D system, which is currently undergoing testing in preparation for submission of a 510(k) amendment. All obligations under the agreement are expressly conditioned upon receipt of FDA clearance, a future regulatory event outside the Company’s control. Following clearance, the agreement will have an initial term of seven years, which may be extended for an additional three years subject to the Company’s achievement of specified annual purchase requirements during the initial term. The Company evaluated this arrangement under FASB ASC 440, Commitments, and concluded that it does not constitute an unconditional purchase obligation under ASC 440-10-50-2 because all purchase obligations are contingent upon receipt of FDA clearance. Accordingly, no disclosure of minimum future purchase commitments is required under ASC 440-10-50-4. The Company further evaluated the arrangement under FASB ASC 450, Contingencies. As of June 30, 2026 and December 31, 2025, receipt of FDA clearance is considered reasonably possible but not probable. Accordingly, no accrual has been recorded, and the financial impact of the arrangement, if any, cannot be reasonably estimated until FDA clearance is obtained. There can be no assurance that FDA clearance will be obtained within the anticipated timeframe or at all. Contingencies – Legal Matters The Company may be subject to litigation claims arising in the ordinary course of business. The Company records litigation accruals for legal matters which are both probable and estimable and for related legal costs as incurred. The Company does not reduce these liabilities for potential insurance or third-party recoveries. As of June 30, 2026 and December 31, 2025, respectively, the Company is not aware of any litigation, pending litigation, or other transactions that require accrual or disclosure.

On July 8, 2025, the Company executed a five-year lease for its office space, covering the period from July 8, 2025 to July 8, 2030. ●Lease term: 60 months (five years) ●Monthly lease payments: ○Months 1-12: $3,626 per month ○Months 13-24: $3,777 per month ○Months 25-60: $4,200 per month ●Total lease payments: $240,036 (excluding variable monthly operating expenses) ●Occupancy date: August 1, 2025 ●Renewal option: The lease has no renewal options. ●Lease classification: The lease is evaluated under FASB ASC 842, Leases, and recorded as a right-of-use (ROU) asset and lease liability based on the present value of lease payments ($196,049) at lease commencement. ●Lease incentives/allowances – none ●Guarantee – The lease is guaranteed by the Company’s Chief Executive Officer. The guarantee is unconditional and continuing, and covers the full performance of the lease obligations, including payment of rent and fulfillment of all tenant responsibilities.

P60M

240036

false

20000 Loss on lease termination of $15,018 was calculated as follows: Schedule of loss on lease termination <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 45%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255); visibility: hidden"> <td style="display: none; text-align: left; visibility: hidden"> </td><td style="display: none; visibility: hidden"> </td> <td style="display: none; text-align: left; visibility: hidden"> </td><td id="xdx_494_20260630_zLxY0BIxEJQa" style="display: none; text-align: right; visibility: hidden"> </td><td style="display: none; text-align: left; visibility: hidden"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: left">Right-of-Use Asset</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAsset_iI_dxL_c20260630_zxAqr9vbcwWa" style="width: 10%; text-align: right" title="Right-of-Use Asset::XDX::160107">28,228</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--CashPaidToTerminateLease_iI_uUSD_z3hrRnEuU57e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cash paid to terminate lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--OperatingLeaseLiabilities_iI_uUSD_zXD9TYejRsDl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(33,210</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_ecustom--LossOnTerminationOfLease_iI_uUSD_zyhXk2F6dCrj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss on lease termination</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,018</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 20000 -33210 15018

On March 17, 2022, the Company executed a five-year lease extension for its office space, covering the period from June 1, 2022, through May 31, 2027. ●Lease term: 60 months (five years) ●Monthly lease payments: ○Years 1-3: $1,600 per month ○Years 4-5: $1,700 per month ●Total lease payments: $57,600 for the first three years and $40,800 for the last two years ●Renewal option: The Company has the option to extend the lease for an additional five years through May 31, 2032. ●Lease classification: The lease is evaluated under FASB ASC 842, Leases, and recorded as a right-of-use (ROU) asset and lease liability based on the present value of lease payments at lease commencement. ●Renewal option assessment: At lease inception, based on historical operations, the Company does not expect to exercise the renewal option and has excluded it from lease liability calculations.

P60M

57600

40800

Renewal option: The Company has the option to extend the lease for an additional five years through May 31, 2032.

The tables below present information regarding the Company’s operating lease asset and liability at June 30, 2026 and December 31, 2025, respectively: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>Schedule of operating lease asset and liability</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left; padding-bottom: 2.5pt">Operating lease - right-of-use asset - non-current</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20260630_zLYgYJ04S6Ji" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right">160,107</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20251231_zHvgNZY5CGl3" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right">179,711</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseLiability_iI_c20260630_zqJ6AkI6Rc6h" style="border-bottom: Black 2.5pt double; text-align: right">169,672</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingLeaseLiability_iI_c20251231_zSbtZ4c3swo" style="border-bottom: Black 2.5pt double; text-align: right">184,298</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average remaining lease term (years)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260630_zYzvTMB1mN6" style="border-bottom: Black 2.5pt double; text-align: right">4.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zPh1fU0NqKy6" style="border-bottom: Black 2.5pt double; text-align: right">4.58</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average discount rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uRatio_c20260630_zFT09vfGqRB7" style="border-bottom: Black 2.5pt double; text-align: right">8</td><td style="padding-bottom: 2pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uRatio_c20251231_zmopXqjqv8c3" style="border-bottom: Black 2.5pt double; text-align: right">8</td><td style="padding-bottom: 2pt; text-align: left">%</td></tr> </table>

160107

179711

169672

184298

P4Y1M2D

P4Y6M29D

0.08

The components of lease expense were as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in">Schedule of operating lease expense</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating lease costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Amortization of right-of-use operating lease asset</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_c20260101__20260630_z1SpGIcXfSO7" style="width: 18%; text-align: right" title="Amortization of right-of-use operating lease asset">19,604</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_c20250101__20250630_zsXsV6MT9MU3" style="width: 18%; text-align: right" title="Amortization of right-of-use operating lease asset">8,065</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">Lease liability expense in connection with obligation repayment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--RepaymentsOfDebtAndCapitalLeaseObligations_c20260101__20260630_zPxxx2B1VBwc" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liability expense in connection with obligation repayment">7,130</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--RepaymentsOfDebtAndCapitalLeaseObligations_c20250101__20250630_zN82hhpiJgwh" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liability expense in connection with obligation repayment">1,635</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in">Total operating lease costs</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--TotalOperatingLeaseCosts_c20260101__20260630_zpinClcHssR4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total operating lease costs">26,734</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--TotalOperatingLeaseCosts_c20250101__20250630_z2DZSiSrZIo" style="border-bottom: Black 2.5pt double; text-align: right" title="Total operating lease costs">9,700</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Supplemental cash flow information related to operating leases was as follows:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in">Operating cash outflows from operating lease (obligation payment)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeasePaymentsUse_c20260101__20260630_zztNZ15tqLs8" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating cash outflows from operating lease (obligation payment)">21,756</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeasePaymentsUse_c20250101__20250630_zYFB2wsJoXik" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating cash outflows from operating lease (obligation payment)">9,700</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in">Right-of-use asset obtained in exchange for new operating lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_dxL_c20260101__20260630_zCknTOsoE4dc" style="border-bottom: Black 2.5pt double; text-align: right" title="Right-of-use asset obtained in exchange for new operating lease liability::XDX::0">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_dxL_c20250101__20250630_znD6z3Z7sBAk" style="border-bottom: Black 2.5pt double; text-align: right" title="Right-of-use asset obtained in exchange for new operating lease liability::XDX::0">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

19604

8065

7130

1635

26734 9700

21756

9700

Future minimum lease payments required under leases that have initial or remaining non-cancelable lease terms in excess of one year at December 31,: Schedule of future minimum lease payments <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2026 (6 months)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20260630_zPj2UMuU73qj" style="width: 12%; text-align: right" title="2026 (6 months)">22,511</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20260630_zRhIiEK6NhKg" style="text-align: right" title="2027">47,439</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20260630_zxFKqYvs2A23" style="text-align: right" title="2028">50,400</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2029</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20260630_zdNYSv7fUUP1" style="text-align: right" title="2029">50,400</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--OperatingLeasesFutureMinimumPaymentDueThereafter_iI_uUSD_c20260630_zRJ1Pi2hsja9" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter">29,400</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total undiscounted cash flows</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20260630_zbOO8msVtFh3" style="text-align: right" title="Total undiscounted cash flows">200,150</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: amount representing interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_c20260630_zp8MpJ5Mnv95" style="border-bottom: Black 1pt solid; text-align: right" title="Less: amount representing interest">30,478</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Present value of operating lease liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--OperatingLeasesLiability_iI_c20260630_z8E2TetPkofc" style="text-align: right" title="Present value of operating lease liability">169,672</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: current portion of operating lease liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20260630_zbtPr8U1fpHd" style="border-bottom: Black 1pt solid; text-align: right" title="Less: current portion of operating lease liability">32,778</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Long-term operating lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20260630_zkqksRzITfO2" style="border-bottom: Black 2.5pt double; text-align: right" title="Long-term operating lease liability">136,894</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

22511

47439

50400

29400

200150

30478

169672

32778

136894

Note 7 – Stockholders’ Equity (Deficit) The Company has two classes of capital stock: preferred stock and common stock. Authorized Capital Structure The Company is authorized to issue 110,000,000 shares of capital stock, consisting of 100,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. On October 27, 2025, the Company filed two Certificates of Amendment with the Texas Secretary of State, each effective as of that date: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">The first amendment reduced the authorized common stock from 6,000,000,000 shares to 100,000,000 shares, reduced the authorized preferred stock from 20,000,000 shares to 10,000,000 shares, and reduced the par value of the preferred stock from $1.00 per share to $0.0001 per share. The par value of the common stock was unchanged.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">The second amendment was a conforming amendment that restated the conversion provisions of the Series A Preferred Stock, including the anti-dilution adjustment formula, to align the Certificate of Formation with the conversion terms in effect since the original designation. The amendment did not modify the economic rights or preferences of the Series A Preferred Stock.</td></tr></table> The board of directors is authorized, without further stockholder approval, to designate one or more series of preferred stock from time to time and to fix the rights, preferences, limitations, and restrictions of each series prior to issuance, including dividend rights, voting rights, redemption terms, conversion and exchange rights, liquidation preferences, and ranking among different series of preferred stock. Preferred Stock - Series Designations Effective March 18, 2026, the Company filed a Certificate of Amendment with the Texas Secretary of State undesignating all previously designated series of preferred stock. The following series were undesignated, and the underlying shares were returned to the authorized but unissued preferred stock pool: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Series A: <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20260318__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3T2EEWPcJM9" title="Preferred Stock Shares Designated">5,450,000 shares</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Series B: <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20260318__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zlrhlFaFGy4e" title="Preferred Stock Shares Designated">9,000,000 shares</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Series C: <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20260318__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zJXLHLJ8IgOc" title="Preferred Stock Shares Designated">840,000 shares</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Series D: <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20260318__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zW9ZITUJ3lhe" title="Preferred Stock Shares Designated">1,560,000 shares</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Series E: <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20260318__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zXbhgG8eCBS1" title="Preferred Stock Shares Designated">1,200,000 shares</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Series F: <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20260318__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zauVYNpx50pl" title="Preferred Stock Shares Designated">600,000 shares</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Series G: <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20260318__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_z3YtMfLlmj1h" title="Preferred Stock Shares Designated">3,000,000 shares</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Series H: <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20260318__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_zezM7lB2fHY6" title="Preferred Stock Shares Designated">15,000,000 shares</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Series S: <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20260318__us-gaap--StatementClassOfStockAxis__custom--SeriesSPreferredStockMember_zJijGifuWkF4" title="Preferred Stock Shares Designated">100,000 shares</td></tr></table> In the aggregate, 36,750,000 shares previously designated across these nine series were returned to the authorized but unissued preferred stock pool. As a result of the undesignation, no series of preferred stock are currently designated, and no shares of preferred stock were issued or outstanding at June 30, 2026. The board of directors retains the authority to designate new series of preferred stock from the authorized 10,000,000 share pool at a future date without further stockholder approval. Series A Preferred Stock Prior to its undesignation, the Company had designated <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zfElMc71bwc3" title="Preferred Stock Shares Designated">5,450,000 shares of Series A 8% Cumulative Convertible Redeemable Preferred Stock at $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zkL49YZYsTH8" title="Preferred Stock, Par Value Per Share">0.0001 par value per share. The material terms of the Series A Preferred Stock were as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZWZpY2l0KSAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_981_ecustom--PreferredStockDividendRights_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zBpHb80RhEr8" style="text-align: justify" title="Preferred Stock, Dividends">Dividends. Holders were entitled to cumulative dividends at a rate of <span id="xdx_905_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uRatio_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zx0t24MOdB5e" title="Preferred Stock, Dividend Rate, Percentage">8% per annum ($0.1064 per share per year), payable semi-annually on January 1 and July 1 of each year. Dividends were payable in cash or, at the Company’s election, in additional shares of Series A Preferred Stock valued at $1.33 per share.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZWZpY2l0KSAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_98E_ecustom--PreferredStockLiquidationPreferences_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zSNEJx2y9rTd" style="text-align: justify" title="Preferred Stock, Liquidation Preference">Liquidation Preference. Upon any liquidation, dissolution, or winding up of the Company, holders were entitled to receive $1.33 per share plus all accumulated and unpaid dividends, prior to any distribution to holders of any other series of preferred stock or common stock.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZWZpY2l0KSAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_98B_eus-gaap--PreferredStockConversionBasis_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z94qkd5hT8cj" style="text-align: justify" title="Preferred Stock, Conversion">Conversion. Each share of Series A Preferred Stock was convertible, at the option of either the Company or the holder, into common stock at a ratio of 1 share of common stock for every 400 shares of Series A Preferred Stock. The conversion ratio was subject to adjustment for stock splits, stock dividends, combinations, reclassifications, and below-market issuances pursuant to a broad-based weighted average anti-dilution formula.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZWZpY2l0KSAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_98D_ecustom--PreferredStockRedemptionRights_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4WPzsFIuyph" style="text-align: justify" title="Preferred Stock, Redemption">Redemption. The Company had the right to redeem the Series A Preferred Stock, in whole or in part, at any time after the second anniversary of the Final Closing Date (as defined in the Certificate of Formation) at a redemption price of $1.46 per share plus all accumulated and unpaid dividends, provided that the common stock had closed at or above $<span id="xdx_90A_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_uUSDPShares_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zqDKqHKKrt7a" title="Preferred Stock, Redemption Price Per Share">2.00 per share for 20 consecutive trading days prior to the redemption notice. The Company was required to provide 30 days’ prior written notice of any redemption.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZWZpY2l0KSAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_988_eus-gaap--PreferredStockVotingRights_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zvotyoqCyoqg" style="text-align: justify" title="Preferred Stock, Voting Rights">Voting Rights. Holders voted together with holders of common stock as a single class on all matters submitted to a vote of stockholders, with each holder entitled to cast one vote for each share of common stock into which such holder’s Series A Preferred Stock was then convertible.</td></tr></table> Series B Preferred Stock Prior to its undesignation, the Company had designated <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zLBqmkGnbp25" title="Preferred Stock Shares Designated">9,000,000 shares of Series B Convertible Preferred Stock at $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zHKnUa6NOMG9" title="Preferred Stock, Par Value Per Share">0.0001 par value per share. The material terms of the Series B Preferred Stock were as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZWZpY2l0KSAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_98B_eus-gaap--PreferredStockConversionBasis_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zowzKaT6w1rb" style="text-align: justify" title="Preferred Stock, Conversion">Conversion. Series B Preferred Stock was convertible into common stock at a contractual ratio of 0.25 shares of common stock per share of Series B Preferred Stock surrendered, subject to adjustment for stock splits and combinations. The Certificate of Designation provided for a 125% conversion factor, resulting in an effective conversion ratio of 0.3125 shares of common stock per share of Series B Preferred Stock.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZWZpY2l0KSAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_981_eus-gaap--PreferredStockVotingRights_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zl21o6bL6DS9" style="text-align: justify" title="Preferred Stock, Voting Rights">Voting Rights. Holders were entitled to 100 votes per share on all matters submitted to a vote of stockholders, voting together with holders of common stock as a single class.</td></tr></table> Conversion of Preferred Stock On October 30, 2025, all <span id="xdx_90F_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_uShares_c20251030__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zyR1t7QsAr66" title="Preferred Stock Shares Converted">435,085 shares of Series A Preferred Stock and all <span id="xdx_904_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_uShares_c20251030__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zOEXChb9GYU4" title="Preferred Stock Shares Converted">192,000 shares of Series B Preferred Stock then issued and outstanding were converted into cSommon stock as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZWZpY2l0KSAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_982_eus-gaap--CommonStockConversionFeatures_c20251029__20251030__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zBNB8zU5Z3z9" style="text-align: justify" title="Conversion to Common Stock">The 435,085 shares of Series A Preferred Stock were converted into 1,101 shares of common stock at the contractual ratio of 1 share of common stock for every 400 shares of Series A Preferred Stock.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZWZpY2l0KSAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_987_eus-gaap--CommonStockConversionFeatures_c20251029__20251030__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zm0XGwooXUO4" style="text-align: justify" title="Conversion to Common Stock">The 192,000 shares of Series B Preferred Stock were converted into 60,009 shares of common stock at the contractual effective ratio of 0.3125 shares of common stock per share of Series B Preferred Stock.</td></tr></table> Fractional shares resulting from each conversion were rounded up to the nearest whole share. Both conversions were accounted for as reclassifications within stockholders’ equity, with the carrying amount of the converted preferred stock reclassified to common stock and additional paid-in capital. No gain or loss was recognized. Following the October 30, 2025 conversions, no shares of preferred stock of any series remained issued and outstanding at December 31, 2025 or June 30, 2026. Common Stock <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">-</td><td style="text-align: justify">100,000,000 shares authorized</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">-</td><td style="text-align: justify">$0.0001 par value</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">-</td><td style="text-align: justify">Voting at 1 vote per share</td></tr></table> Equity Transactions for the Six Months Ended June 30, 2026 Stock Issued for Services The Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_uShares_c20260101__20260630__us-gaap--TransactionTypeAxis__custom--ServicesMember_zF2H3W6Bi6a4" title="Common Stock, Shares, Issued">50,000 shares of common stock to a consultant for services rendered, having a fair value of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20260101__20260630__us-gaap--TransactionTypeAxis__custom--ServicesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7orzbHNl7p9">94,500 ($1.89/share), based upon the quoted closing trading price on the grant date. Cancellation of Shares The Company cancelled <span id="xdx_906_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxw82zJz3hWb" title="Cancellation of Shares, Shares">3,125 shares of common stock related to a prior period conversion of Series A Convertible Preferred Stock to common stock. Equity Transactions for the Year Ended December 31, 2025 Stock Issued for Cash The Company issued 9,333,333 shares of common stock for $10,000,000 ($<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20251231__srt--RangeAxis__srt--MinimumMember__us-gaap--TransactionTypeAxis__custom--CashPaymentsMember_zDGZxmeZN7sj" title="Common Stock Per Share">1.00 - $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20251231__srt--RangeAxis__srt--MaximumMember__us-gaap--TransactionTypeAxis__custom--CashPaymentsMember_znHYxkkbG0hi" title="Common Stock Per Share">1.50/share). Of the total shares issued, <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20251231__us-gaap--TransactionTypeAxis__custom--CashPaymentsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zp7NXDmj6re3" title="Common Stock, Shares, Issued">8,000,000 were sold to a related party, who is a principal stockholder for $<span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20251231__us-gaap--TransactionTypeAxis__custom--CashPaymentsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PrincipalStockholderMember_ztCi0IyeLMvi" title="Common Stock, Shares, Issued">8,000,000. Common Stock Repurchase Agreement The Company repurchased <span id="xdx_902_eus-gaap--TreasuryStockSharesAcquired_pid_uShares_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z5wGuUGcgZg3" title="Repurchase of common stock">4,000,000 shares of common stock from a stockholder for $2,500,000 ($<span id="xdx_903_eus-gaap--TreasuryStockAcquiredAverageCostPerShare_pid_uUSDPShares_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--RangeAxis__srt--MinimumMember_zLUxABYdzZWg" title="Shares Acquired, Average Cost Per Share">0.60 - <span id="xdx_905_eus-gaap--TreasuryStockAcquiredAverageCostPerShare_pid_uUSDPShares_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--RangeAxis__srt--MaximumMember_zbpfrUIF4X4d" title="Shares Acquired, Average Cost Per Share">0.75/share). The repurchased shares were cancelled and retired upon acquisition and are no longer considered issued or outstanding. In accordance with FASB ASC 505-30, “Equity – Treasury Stock”, and consistent with the Company’s corporate charter and applicable state law, the cancelled shares were returned to the status of authorized but unissued, thereby increasing the number of shares available for future issuance. The repurchase will be accounted for as a reduction to stockholders’ equity, with the purchase price allocated entirely to Additional Paid-in Capital (“APIC”), as the Company had sufficient APIC available from prior issuances. No gain or loss will be recognized in connection with this transaction. The cash outflow related to the stock repurchase will be classified as a financing activity in the statement of cash flow. In conjunction with the stock repurchase, the Company also issued 500,000 freestanding warrants to the selling stockholder. The warrants have an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zepOVpWuYEDf" title="Warrants Exercised price">1 and expire on December 31, 2026. The warrants were classified as equity instruments and recorded at fair value, with a corresponding credit to APIC. As the warrants were issued as part of the consideration for the share repurchase, their fair value was included in the total cost of the repurchase transaction, resulting in a net effect of $0 on total stockholders’ equity. See Note 9 for warrants. Stock Issued for Services The Company issued 100,000 shares of common stock to a consultant for services rendered, having a fair value of $177,000 ($1.77/share), based upon the quoted closing trading price on the grant date.

100000000

0.0001

10000000

0.0001

100000000

10000000

0.0001

5450000

9000000

840000

1560000

1200000

600000

3000000

15000000

100000

36750000

5450000

0.0001

Dividends. Holders were entitled to cumulative dividends at a rate of 8% per annum ($0.1064 per share per year), payable semi-annually on January 1 and July 1 of each year. Dividends were payable in cash or, at the Company’s election, in additional shares of Series A Preferred Stock valued at $1.33 per share.

0.08

Liquidation Preference. Upon any liquidation, dissolution, or winding up of the Company, holders were entitled to receive $1.33 per share plus all accumulated and unpaid dividends, prior to any distribution to holders of any other series of preferred stock or common stock.

Conversion. Each share of Series A Preferred Stock was convertible, at the option of either the Company or the holder, into common stock at a ratio of 1 share of common stock for every 400 shares of Series A Preferred Stock. The conversion ratio was subject to adjustment for stock splits, stock dividends, combinations, reclassifications, and below-market issuances pursuant to a broad-based weighted average anti-dilution formula.

Redemption. The Company had the right to redeem the Series A Preferred Stock, in whole or in part, at any time after the second anniversary of the Final Closing Date (as defined in the Certificate of Formation) at a redemption price of $1.46 per share plus all accumulated and unpaid dividends, provided that the common stock had closed at or above $2.00 per share for 20 consecutive trading days prior to the redemption notice. The Company was required to provide 30 days’ prior written notice of any redemption.

2.00

Voting Rights. Holders voted together with holders of common stock as a single class on all matters submitted to a vote of stockholders, with each holder entitled to cast one vote for each share of common stock into which such holder’s Series A Preferred Stock was then convertible.

9000000

0.0001

Conversion. Series B Preferred Stock was convertible into common stock at a contractual ratio of 0.25 shares of common stock per share of Series B Preferred Stock surrendered, subject to adjustment for stock splits and combinations. The Certificate of Designation provided for a 125% conversion factor, resulting in an effective conversion ratio of 0.3125 shares of common stock per share of Series B Preferred Stock.

Voting Rights. Holders were entitled to 100 votes per share on all matters submitted to a vote of stockholders, voting together with holders of common stock as a single class.

435085

192000

The 435,085 shares of Series A Preferred Stock were converted into 1,101 shares of common stock at the contractual ratio of 1 share of common stock for every 400 shares of Series A Preferred Stock.

The 192,000 shares of Series B Preferred Stock were converted into 60,009 shares of common stock at the contractual effective ratio of 0.3125 shares of common stock per share of Series B Preferred Stock.

100000000

0.0001

Voting at 1 vote per share

50000

94500

1.89

3125

9333333

10000000

1.00

1.50

8000000

4000000

2500000

0.60

0.75

500000

100000

177000

1.77

Note 8 - Stock Option Plan In May 2021, the Company adopted an equity incentive plan (the “Plan”). Under the Plan, the Company may grant up to 10,000,000 stock options to eligible participants. All terms for stock options granted under the Plan will be set by the Board of Directors. Stock Option Grants On November 5, 2025, the Company granted stock options to certain executives and employees to purchase an aggregate of 5,150,000 shares of the Company’s common stock at an exercise price of $1.48 per share. The options have a contractual term of five (5) years and were fully vested on the grant date. The grant was approved by the Board of Directors and was made pursuant to the Plan. After giving effect to the November 5, 2025 grant, 4,850,000 shares remained available for future issuance under the Plan at both June 30, 2026 and December 31, 2025. Of the total grant, <span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted_iI_pid_uShares_c20251105__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsChairmanAndPresidentMember_zDgKBlvLTA4d" title="Stock Options Granted to Chairman of the Board of Directors and President">1,500,000 options were granted to the Company’s Chairman of the Board of Directors and President and <span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted_iI_pid_uShares_c20251105__srt--TitleOfIndividualAxis__srt--VicePresidentMember__srt--TitleOfIndividualAxis__custom--BoardsOfDirectorsMember_zP3uV5aYEUnk" title="Stock Options Granted to a member of the Board of Directors">750,000 options were granted each to a member of the Board of Directors and the Company’s Vice-President. The aggregate grant date fair value of stock options granted during the year ended December 31, 2025 was $4,982,588. The weighted average grant date fair value per option was $<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20250101__20251231_zMcuEnr1rPKb" title="Weighted Average Grant Date Fair Value per Option">0.97. Valuation Methodology and Assumptions The fair value of stock options granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: Schedule of fair value of stock options <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 37%">Exercise price</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20260630_zch2wPzACgCa" style="width: 10%; text-align: right" title="Exercise price">1.48</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQsjQA5y3dP2" title="Expected term">2.5 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uRatio_c20260101__20260630_zlRqYH801iT1" style="text-align: right" title="Expected volatility">115</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uRatio_c20260101__20260630_zUpFvG0vEgte" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uRatio_c20260101__20260630_z5f0ykGWS9W8" style="text-align: right" title="Risk free interest rate">3.63</td><td style="text-align: left">%</td></tr> </table> Stock Option activity for the six months ended June 30, 2026 and the year ended December 31, 2025 are summarized as follows: Schedule of stock options activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="font-weight: bold; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">Outstanding - December 31, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20250101__20251231_zNqwKJFSQtb1" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Beginning">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">Exercisable - December 31, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_pid_uShares_c20250101__20251231_zSr2wacmyCNh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Vested and Exercisable, Beginning">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Granted</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20250101__20251231_zmW2BTEVFSzd" style="width: 10%; text-align: right" title="Number of Options Granted">5,150,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20250101__20251231_zrRzoGAfe0rg" style="width: 10%; text-align: right" title="Weighted Average Exercise Price Granted">1.48</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zyXIr1t3lGCk" title="Weighted Average Remaining Contractual Term (Years), Granted">4.85</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--WeightedAverageGrantDateFairValuePriceGranted_pid_uUSDPShares_c20250101__20251231_zGBdBoBGKHZ4" style="width: 10%; text-align: right" title="Weighted Average Grant Date Fair Value Price Granted">0.97</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20250101__20251231_z2NX1i8eFGVd" style="text-align: right" title="Number of Options Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">Cancelled/Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_pid_uShares_c20250101__20251231_z2FvcgGQiXnc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Cancelled/Forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">Outstanding - December 31, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20260101__20260630_znuVxgnz56sa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Ending">5,150,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20251231_ztPmUd9sNBG1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding">1.48</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zFYhgYYJEKb1" title="Weighted Average Remaining Contractual Term (Years), Outstanding">4.85</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">Exercisable - December 31, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_pid_uShares_c20260101__20260630_zFeq80u1ChU5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Vested and Exercisable, Ending">5,150,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20251231_zR0Xjd3K8ode" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Vested and Exercisable">1.48</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zJ1p4Z2iy1fh" title="Weighted Average Remaining Contractual Term (Years),Vested and Exercisable">4.85</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20260101__20260630_ztTtzX4qxui1" style="text-align: right" title="Number of Options Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20260101__20260630_zz5W7qTMNcD" style="text-align: right" title="Number of Options Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">Cancelled/Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_pid_uShares_c20260101__20260630_zaKFK1Hr5lyc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Cancelled/Forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">Outstanding - June 30, 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20260101__20260630_zBU5G451xic3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Ending">5,150,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20260630_zqib1HQoUccg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding">1.48</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630_zGAjO18mG0f9" title="Weighted Average Remaining Contractual Term (Years), Outstanding">4.35</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20260101__20260630_z6G0k8XAPs45" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending">1,339,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">Exercisable - June 30, 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_uShares_c20260101__20260630_zdE8LAv9GG69" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Vested and Exercisable, Ending">5,150,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20260630_z4eVTGcVIjWj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Vested and Exercisable">1.48</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630_zQGbw0F9xTNb" title="Weighted Average Remaining Contractual Term (Years),Vested and Exercisable">4.35</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20260101__20260630_zbil6yHW456f" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value Exercisable, Ending">1,339,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> Compensation Expense The Company recognized stock-based compensation expense of $4,982,588 related to stock options for the year ended December 31, 2025, which was included in general and administrative expenses in those statements of operations. As the options were fully vested on the grant date, there was no unrecognized compensation cost related to stock options as of December 31, 2025. 10000000

5150000

1.48 P5Y

4850000

1500000 750000

4982588

0.97

The fair value of stock options granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: Schedule of fair value of stock options <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 37%">Exercise price</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20260630_zch2wPzACgCa" style="width: 10%; text-align: right" title="Exercise price">1.48</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQsjQA5y3dP2" title="Expected term">2.5 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uRatio_c20260101__20260630_zlRqYH801iT1" style="text-align: right" title="Expected volatility">115</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uRatio_c20260101__20260630_zUpFvG0vEgte" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uRatio_c20260101__20260630_z5f0ykGWS9W8" style="text-align: right" title="Risk free interest rate">3.63</td><td style="text-align: left">%</td></tr> </table>

1.48

P2Y6M

1.15

0.0363

Stock Option activity for the six months ended June 30, 2026 and the year ended December 31, 2025 are summarized as follows: Schedule of stock options activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="font-weight: bold; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">Outstanding - December 31, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20250101__20251231_zNqwKJFSQtb1" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Beginning">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">Exercisable - December 31, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_pid_uShares_c20250101__20251231_zSr2wacmyCNh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Vested and Exercisable, Beginning">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Granted</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20250101__20251231_zmW2BTEVFSzd" style="width: 10%; text-align: right" title="Number of Options Granted">5,150,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20250101__20251231_zrRzoGAfe0rg" style="width: 10%; text-align: right" title="Weighted Average Exercise Price Granted">1.48</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zyXIr1t3lGCk" title="Weighted Average Remaining Contractual Term (Years), Granted">4.85</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--WeightedAverageGrantDateFairValuePriceGranted_pid_uUSDPShares_c20250101__20251231_zGBdBoBGKHZ4" style="width: 10%; text-align: right" title="Weighted Average Grant Date Fair Value Price Granted">0.97</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20250101__20251231_z2NX1i8eFGVd" style="text-align: right" title="Number of Options Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">Cancelled/Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_pid_uShares_c20250101__20251231_z2FvcgGQiXnc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Cancelled/Forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">Outstanding - December 31, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20260101__20260630_znuVxgnz56sa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Ending">5,150,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20251231_ztPmUd9sNBG1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding">1.48</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zFYhgYYJEKb1" title="Weighted Average Remaining Contractual Term (Years), Outstanding">4.85</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">Exercisable - December 31, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_pid_uShares_c20260101__20260630_zFeq80u1ChU5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Vested and Exercisable, Ending">5,150,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20251231_zR0Xjd3K8ode" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Vested and Exercisable">1.48</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zJ1p4Z2iy1fh" title="Weighted Average Remaining Contractual Term (Years),Vested and Exercisable">4.85</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20260101__20260630_ztTtzX4qxui1" style="text-align: right" title="Number of Options Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20260101__20260630_zz5W7qTMNcD" style="text-align: right" title="Number of Options Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">Cancelled/Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_pid_uShares_c20260101__20260630_zaKFK1Hr5lyc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Cancelled/Forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">Outstanding - June 30, 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20260101__20260630_zBU5G451xic3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Ending">5,150,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20260630_zqib1HQoUccg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding">1.48</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630_zGAjO18mG0f9" title="Weighted Average Remaining Contractual Term (Years), Outstanding">4.35</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20260101__20260630_z6G0k8XAPs45" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending">1,339,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">Exercisable - June 30, 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_uShares_c20260101__20260630_zdE8LAv9GG69" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Vested and Exercisable, Ending">5,150,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20260630_z4eVTGcVIjWj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Vested and Exercisable">1.48</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630_zQGbw0F9xTNb" title="Weighted Average Remaining Contractual Term (Years),Vested and Exercisable">4.35</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20260101__20260630_zbil6yHW456f" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value Exercisable, Ending">1,339,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

5150000

1.48

P4Y10M6D 0.97

5150000

1.48

P4Y10M6D

5150000

1.48

P4Y10M6D

5150000

1.48

P4Y4M6D

1339000

5150000

1.48

P4Y4M6D

1339000

4982588

Note 9 – Warrants Warrant activity for the six months ended June 30, 2026 and the year ended December 31, 2025 are summarized as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none"> <td style="display: none"> Schedule of warrant activity</td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; width: 39%; text-align: left">Outstanding - December 31, 2024</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iS_pid_uShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1bDiLupOyQh" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning">1,600,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zx2DXEVIFshb" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning">0.24</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span id="xdx_908_ecustom--WeightedAverageRemainingContractualTermYearsOutstanding_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr9xDUka0t13" title="Weighted Average Remaining Contractual Term (Years), Outstanding">1.63</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstanding_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIxEXEOGf394" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning">1,231,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left">Exercisable - December 31, 2024</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--NumberOfWarrantsExercisable_iS_pid_uShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwlGYEKycuS1" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Exercisable, Beginning">1,600,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_ecustom--WeightedaverageexercisePriceExercisable_iS_pid_uUSDPShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdapmYKch1Ab" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercisable, Beginning">0.24</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_ecustom--WeightedAverageRemainingContractualTermYearsExercisable_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z85vnCs48Tuh" title="Weighted Average Remaining Contractual Term (Years), Exercisable">1.63</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_ecustom--WarrantsAndRightsExercisable_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJdwiRv3RHT7" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value Exercisable, Beginning">1,231,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--NumberOfWarrantsGranted_pid_uShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKGDAw577oJc" style="text-align: right" title="Number of Warrants Granted">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--WeightedaverageexercisePriceGranted_pid_uUSDPShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXekHHdi14xe" style="text-align: right" title="Weighted Average Exercise Price Granted">1.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Exercised</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--NumberOfWarrantsExercised_pid_d0_uShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zglGNHiAxYu1" style="text-align: right" title="Number of Warrants Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: left">Cancelled/Forfeited</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--NumberOfWarrantsCancelledforfeited_pid_d0_uShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzM4GWUhW1Hb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Cancelled/Forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left">Outstanding - December 31, 2025</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iS_pid_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zICRYKO7ucX5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Outstanding, Beginning">2,100,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zd45MpquT9h9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning">0.42</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_ecustom--WeightedAverageRemainingContractualTermYearsOutstanding_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcfigntcegO8" title="Weighted Average Remaining Contractual Term (Years), Outstanding">1.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstanding_iS_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIyV05l7QkQ5" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning">2,622,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: left">Exercisable - December 31, 2025</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--NumberOfWarrantsExercisable_iS_pid_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6IooPTzu24h" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Exercisable, Beginning">2,100,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_ecustom--WeightedaverageexercisePriceExercisable_iS_pid_uUSDPShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGDEU3rrGjD4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercisable, Beginning">0.42</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_ecustom--WeightedAverageRemainingContractualTermYearsExercisable_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zglEadiOPDWg" title="Weighted Average Remaining Contractual Term (Years), Exercisable">1.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_ecustom--WarrantsAndRightsExercisable_iS_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYQicYtyag1h" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value Exercisable, Beginning">2,622,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--NumberOfWarrantsGranted_pid_d0_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQ2domrlmvB8" style="text-align: right" title="Number of Warrants Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Exercised</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--NumberOfWarrantsExercised_pid_d0_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXAQbuxccPT4" style="text-align: right" title="Number of Warrants Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left">Cancelled/Forfeited</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--NumberOfWarrantsCancelledforfeited_pid_d0_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZXw4GBBqz58" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Cancelled/Forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: left">Outstanding - June 30, 2026</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iE_pid_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCxVYFCLwrpc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Outstanding, Ending">2,100,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_uUSDPShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPHn99FfVpQa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending">0.42</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_ecustom--WeightedAverageRemainingContractualTermYearsOutstanding_dtY_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaqZUcmQk1Tl" title="Weighted Average Remaining Contractual Term (Years), Outstanding">0.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstanding_iE_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHowaE4CzIBd" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending">2,769,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left">Exercisable - June 30, 2026</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--NumberOfWarrantsExercisable_iE_pid_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2et9EuHDUj3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Exercisable, Ending">2,100,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_ecustom--WeightedaverageexercisePriceExercisable_iE_pid_uUSDPShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo3UMarPli94" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercisable, Ending">0.42</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_ecustom--WeightedAverageRemainingContractualTermYearsExercisable_dtY_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2nyPzjkBEGf" title="Weighted Average Remaining Contractual Term (Years), Exercisable">0.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_ecustom--WarrantsAndRightsExercisable_iE_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOfqHVlqaE05" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value Exercisable, Ending">2,769,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> In December 2024, the Company extended the maturity dates of 1,000,000 warrants from December 31, 2024 to December 31, 2026. The value resulting from this modification was not considered material to the financial statements. In December 2025, the Company extended the maturity dates of 600,000 warrants from December 31, 2025 to December 31, 2026. The value resulting from this modification was not considered material to the financial statements.

Warrant activity for the six months ended June 30, 2026 and the year ended December 31, 2025 are summarized as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none"> <td style="display: none"> Schedule of warrant activity</td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td> <td style="display: none"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; width: 39%; text-align: left">Outstanding - December 31, 2024</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iS_pid_uShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1bDiLupOyQh" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning">1,600,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zx2DXEVIFshb" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning">0.24</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span id="xdx_908_ecustom--WeightedAverageRemainingContractualTermYearsOutstanding_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr9xDUka0t13" title="Weighted Average Remaining Contractual Term (Years), Outstanding">1.63</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstanding_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIxEXEOGf394" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning">1,231,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left">Exercisable - December 31, 2024</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--NumberOfWarrantsExercisable_iS_pid_uShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwlGYEKycuS1" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Exercisable, Beginning">1,600,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_ecustom--WeightedaverageexercisePriceExercisable_iS_pid_uUSDPShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdapmYKch1Ab" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercisable, Beginning">0.24</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_ecustom--WeightedAverageRemainingContractualTermYearsExercisable_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z85vnCs48Tuh" title="Weighted Average Remaining Contractual Term (Years), Exercisable">1.63</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_ecustom--WarrantsAndRightsExercisable_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJdwiRv3RHT7" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value Exercisable, Beginning">1,231,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--NumberOfWarrantsGranted_pid_uShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKGDAw577oJc" style="text-align: right" title="Number of Warrants Granted">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--WeightedaverageexercisePriceGranted_pid_uUSDPShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXekHHdi14xe" style="text-align: right" title="Weighted Average Exercise Price Granted">1.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Exercised</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--NumberOfWarrantsExercised_pid_d0_uShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zglGNHiAxYu1" style="text-align: right" title="Number of Warrants Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: left">Cancelled/Forfeited</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--NumberOfWarrantsCancelledforfeited_pid_d0_uShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzM4GWUhW1Hb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Cancelled/Forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left">Outstanding - December 31, 2025</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iS_pid_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zICRYKO7ucX5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Outstanding, Beginning">2,100,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zd45MpquT9h9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning">0.42</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_ecustom--WeightedAverageRemainingContractualTermYearsOutstanding_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcfigntcegO8" title="Weighted Average Remaining Contractual Term (Years), Outstanding">1.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstanding_iS_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIyV05l7QkQ5" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning">2,622,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: left">Exercisable - December 31, 2025</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--NumberOfWarrantsExercisable_iS_pid_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6IooPTzu24h" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Exercisable, Beginning">2,100,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_ecustom--WeightedaverageexercisePriceExercisable_iS_pid_uUSDPShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGDEU3rrGjD4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercisable, Beginning">0.42</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_ecustom--WeightedAverageRemainingContractualTermYearsExercisable_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zglEadiOPDWg" title="Weighted Average Remaining Contractual Term (Years), Exercisable">1.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_ecustom--WarrantsAndRightsExercisable_iS_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYQicYtyag1h" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value Exercisable, Beginning">2,622,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--NumberOfWarrantsGranted_pid_d0_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQ2domrlmvB8" style="text-align: right" title="Number of Warrants Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Exercised</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--NumberOfWarrantsExercised_pid_d0_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXAQbuxccPT4" style="text-align: right" title="Number of Warrants Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left">Cancelled/Forfeited</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--NumberOfWarrantsCancelledforfeited_pid_d0_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZXw4GBBqz58" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Cancelled/Forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: left">Outstanding - June 30, 2026</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iE_pid_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCxVYFCLwrpc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Outstanding, Ending">2,100,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_uUSDPShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPHn99FfVpQa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending">0.42</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_ecustom--WeightedAverageRemainingContractualTermYearsOutstanding_dtY_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaqZUcmQk1Tl" title="Weighted Average Remaining Contractual Term (Years), Outstanding">0.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstanding_iE_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHowaE4CzIBd" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending">2,769,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left">Exercisable - June 30, 2026</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--NumberOfWarrantsExercisable_iE_pid_uShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2et9EuHDUj3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Exercisable, Ending">2,100,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_ecustom--WeightedaverageexercisePriceExercisable_iE_pid_uUSDPShares_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo3UMarPli94" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercisable, Ending">0.42</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_ecustom--WeightedAverageRemainingContractualTermYearsExercisable_dtY_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2nyPzjkBEGf" title="Weighted Average Remaining Contractual Term (Years), Exercisable">0.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_ecustom--WarrantsAndRightsExercisable_iE_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOfqHVlqaE05" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value Exercisable, Ending">2,769,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

1600000

0.24

P1Y7M17D

1231000

1600000 0.24 P1Y7M17D 1231000 500000 1.00 -0 -0

2100000

0.42

P1Y

2622000

2100000 0.42 P1Y 2622000 -0 -0 -0

2100000

0.42

P0Y6M

2769000

2100000 0.42 P0Y6M 2769000 the Company extended the maturity dates of 1,000,000 warrants from December 31, 2024 to December 31, 2026. the Company extended the maturity dates of 600,000 warrants from December 31, 2025 to December 31, 2026.

Note 10 – Subsequent Events Line of Credit Agreement, Warrant Issuance and Warrant Exercise - Related Party A. Line of Credit Agreement with a Related Party On August 13, 2026, the Company entered into a line of credit agreement with an individual who is a significant stockholder of the Company and accordingly a related party (the “Related Party Lender”), providing a revolving line of credit in the maximum aggregate principal amount of $<span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_uUSD_c20260813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWLfk1lkbW5g" title="Line of credit maximum aggregate principal amount">2,000,000, evidenced by a promissory note issued August 13, 2026 and maturing August 13, 2028. Advances bear interest at a fixed rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uRatio_c20260813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdUQ3mCtYqc3" title="Interest rate, stated percentage">12% per annum and accrue only on amounts actually advanced. Interest is payable quarterly in arrears, with interest only due through August 13, 2027 and principal payable in addition to interest from August 13, 2027 through August 13, 2028. The Company may prepay at any time without premium or penalty, and amounts repaid may be reborrowed. The line of credit is unsecured and is not guaranteed. Draws are subject to the following limitations: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Aggregate advances may not exceed $500,000 during any single calendar quarter.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Each advance must be at least $100,000, or the lesser amount then remaining available.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">The Company must give the lender fourteen (14) days written notice of each requested advance.</td></tr></table> Proceeds are restricted to working capital, commercialization of the Company's positron emission tomography and computed tomography (PET-CT) imaging platform, customer installations, inventory and strategic growth initiatives. Without the prior written consent of the lender, the Company may not: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 36pt"></td><td style="width: 27pt">(i)</td><td style="text-align: justify">liquidate, dissolve or wind up its business;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 36pt"></td><td style="width: 27pt">(ii)</td><td style="text-align: justify">effect any merger or consolidation; or</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 36pt"></td><td style="width: 27pt">(iii)</td><td style="text-align: justify">dispose of all or substantially all of its assets.</td></tr></table> Events of default under the agreement include the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Failure to pay interest when due, continuing ten (10) business days after written notice.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Failure to pay principal when due.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Material misrepresentation, or breach of any other covenant continuing thirty (30) days after written notice.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Specified insolvency, bankruptcy and receivership events.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">The occurrence of a material adverse event.</td></tr></table> Upon an event of default the lender may declare all outstanding principal and accrued and unpaid interest immediately due and payable, and the outstanding principal balance bears interest at <span id="xdx_90F_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uRatio_c20260801__20260813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zv3WHRIaAsc6" title="Outstanding principal balance bearing interest">18% per annum, or the maximum rate permitted by applicable law if lower. No advances had been drawn under the line of credit through August 14, 2026. B. Warrants Issued in Connection with the Line of Credit In consideration of the lender's commitment to provide the line of credit, on August 13, 2026 the Company issued to the Related Party Lender warrants to purchase 300,000 shares of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20260813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjqc9uCP0cti" title="Warrants exercised price">1.50/share, expiring December 31, 2030. The warrants remain outstanding whether or not any advance is made under the line of credit. Upon an event of default in the payment of interest or principal, the exercise price of the warrants is automatically reduced to $1/share, effective as of the date of the default. The fair value of the warrants will be determined on the issuance date using the Black-Scholes-Merton option pricing model, recorded as a deferred financing cost and amortized ratably over the twenty-four (24) month term of the arrangement from August 13, 2026 through August 13, 2028. Deferral and presentation of the cost as an asset, rather than as a reduction of a debt liability, follows the Securities and Exchange Commission staff guidance at ASC 835-30-S45-1 applicable to line-of-credit arrangements, under which the cost is amortized over the term of the arrangement regardless of whether any borrowings are outstanding. The Company evaluated the warrants under ASC 815-40, Derivatives and Hedging - Contracts in Entity's Own Equity. The number of shares is fixed at 300,000, the exercise price is fixed at $1.50/share and is fixed at $1/share in the event of a payment default, and the reduction in the exercise price is contingent on the Company's own credit standing, which ASC 815-40-15-7E identifies as an input to the fair value of a fixed-for-fixed option on equity shares. The warrants are indexed to the Company's own common stock, meet the conditions for equity classification, and will be recorded in additional paid-in capital. C. Exercise of Previously Issued Warrants On August 13, 2026, the Related Party Lender exercised 250,000 previously issued warrants, separate from the 300,000 warrants described above, at an exercise price of $1/share for aggregate exercise proceeds of $250,000. The exercise price had not been received by the Company as of August 14, 2026, and the Company will record the issuance of the 250,000 shares of common stock and the related proceeds of $250,000 upon receipt of the exercise price.

2000000

0.12

500000

0.18

300000

1.50

the Related Party Lender exercised 250,000 previously issued warrants, separate from the 300,000 warrants described above, at an exercise price of $1/share for aggregate exercise proceeds of $250,000. The exercise price had not been received by the Company as of August 14, 2026, and the Company will record the issuance of the 250,000 shares of common stock and the related proceeds of $250,000 upon receipt of the exercise price. false false false false During the period covered by this Quarterly Report on Form 10-Q, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.